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Resumo 
A mitocôndria desempenha um papel central na regulação do metabolismo celular. Como 
consequência, desempenha um papel importante numa grande variedade de condições 
patológicas, tais como: doenças neurodegenerativas, cancro, diabetes e envelhecimento. A 
actividade mitocondrial é em grande parte dependente da disponibilidade de nutrientes no 
meio ambiente e da sua conversão em energia útil. A conversão de macronutrientes, como 
por exemplo açúcares, lípidos e proteínas, em moléculas de elevado potencial energético tais 
como: adenosina trifosfato (ATP), acetil-coenzima A (acetil-CoA), S-adenosil-metionina (SAM) 
e nicotinamida adenina dinucleotídeo (NADH), ocorre através da mitocôndria e da glicólise. O 
ATP, a acetil-CoA, a SAM e a NAD+/NADH, por sua vez, são substratos de alta energia 
utilizados para reações de fosforilação de proteínas (incluindo histonas), 
acetilação/desacetilação de proteínas e metilação de proteínas e ADN, contribuindo assim 
para a regulação de várias vias celulares e para a remodelação epigenética da cromatina. 
Deste modo, a inter-relação entre o ADN mitocondrial e o metabolismo celular, tem um papel 
crucial na manutenção dos níveis de co-factores essenciais para o funcionamento de enzimas 
responsáveis pela regulação da epigenética celular, nomeadamente, regulação da metilação 
do ADN e acetilação de proteínas. As mutações no ADN mitocondrial, na sua maioria, induzem 
defeitos na fosforilação oxidativa. A disfunção mitocondrial e especialmente, a disfunção 
mitocondrial causada por mutações no ADN mitocondrial, têm sido implicadas numa grande 
variedade de patologias relacionadas com a idade. Na verdade, os defeitos em genes 
mitocondriais podem simular praticamente todos os sintomas associados com as doenças 
complexas comuns, confirmando a importância da bioenergética mitocondrial na saúde.  
O principal objectivo deste estudo foi revelar de que forma as mutações patogénicas no ADN 
mitocondrial e/ou variantes mitocondriais podem levar a mudanças epigenéticas, quer no 
padrão de metilação do ADN quer no padrão de acetilação de histonas e outras proteínas. 
Os nossos resultados demonstraram que a disfunção mitocondrial, causada por mutações no 
ADN mitocondrial, pela ausência de ADN mitocondrial, bem como pela presença de algumas 
variantes mitocondriais (ADN mitocondrial pertencente a diferentes haplogrupos), induz 
alterações no perfil metabólico da célula, na actividade do complexo I mitocondrial, na 
metilação do ADN e na acetilação de proteínas. Além disso, observou-se que a disfunção 
mitocondrial causada pela ausência de ADN mitocondrial, conduz ao reajustamento de vários 
processos celulares, através de alterações no grau de acetilação de várias proteínas, 
contribuindo para homeostasia celular e deste modo garantíndo a sobrevivência da célula. 
XXII 
 
 
Palavras chave: Mitocôndria; ADN mitocondrial; fosforilação oxidativa; metilação de ADN;  
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Summary  
Mitochondria have a central role in energy uptake and energy production, and as consequence 
they play a key role in a wide variety of pathological conditions, such as cancer 
neurodegenerative diseases, diabetes and aging. The mitochondrial activity is largely 
dependent on the environmental availability of nutrients and their conversion to usable energy 
that takes place by the conversion, by mitochondrion and by glycolysis, of energy rich 
compounds, such as carbohydrates and fats, into adenosine triphosphate (ATP), acetyl- 
Coenzyme A (Acetyl-CoA), S-adenosylmethionine (SAM), and nicotinamide adenine 
dinucleotide (NADH). ATP, acetyl-CoA, SAM, and NAD+/NADH, in turn, are the high-energy 
substrates for protein (including histones) phosphorylation, acetylation and deacetylation 
reactions, and DNA and protein methylation, thus contributing to regulation of several cell 
pathways and epigenetic and chromatin remodelling. Thus, the interrelationship between 
mtDNA and cell metabolism have an essential role in the maintenance of the levels of essential 
co-factors for epigenetic mechanism such as DNA methylation and acetylation reactions.   
Mutations in the mitochondrial DNA (mtDNA), most of the time induce defects in oxidative 
phosphorylation (OXPHOS). Mitochondrial dysfunction, and especially mitochondrial 
dysfunction caused by mutations in mtDNA have been implicated in a wide range of age related 
pathologies. Indeed, mitochondrial gene defects can result in virtually all of the symptoms 
associated with the common complex diseases, confirming the importance of mitochondrial 
bioenergetics in health.  
The main goal of this study was to unveil how pathogenic mutations in mtDNA and/or 
mitochondrial variants may lead to epigenetic changes, namely alterations in the pattern of 
nuclear DNA methylation and/or acetylation of histones and other proteins. 
Our data, showed that mitochondrial dysfunction, caused either by mtDNA mutations or 
absence of mtDNA, as well as the presence of some mitochondrial variants (different mtDNA 
haplogroups) induce changes in cell metabolic profile, complex I activity, DNA methylation and 
protein acetylation. Furthermore, we observed that mitochondrial dysfunction caused by 
depletion of mtDNA, leads to the readjustment of several cellular processes through the 
acetylation of several proteins, allowing the cell to survive and maintain its homeostasis. 
 
Key words: Mitochondria; mtDNA; OXPHOS; DNA methylation; protein acetylation,  
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1.1 Cellular metabolism  
Metabolism is broadly defined as the sum of biochemical processes in living organisms that 
either produce or consume energy. The metabolism can be simplified to those pathways 
involving abundant nutrients such as carbohydrates, fatty acids and amino acids, essential for 
energy and macromolecular synthesis in humans (Figure 1). The metabolic pathways could be 
conveniently separated into three classes:  anabolism - that synthesize simple molecules or 
polymerize them into more complex macromolecules; catabolism - that degrades molecules to 
generate/release energy; and the pathway that help to eliminate toxic waste produced by the 
other two classes (DeBerardinis and Thompson, 2012). 
 
Figure 1. An overview of Intermediary Metabolism A simplified view of the metabolic pathways, focusing on the major nutrients 
(glucose, amino acids and fatty acids) to produce or store energy and to grow (DeBerardinis and Thompson, 2012). 
Defining these pathways and understanding their physiological roles are among the most 
successful searches in biological research. It was between the 1920s and 1960s, defined as 
the “golden age of biochemistry”, that most of the metabolism network responsible for nutrient 
utilization and energy production was defined in humans. These metabolic networks include 
activities like glycolysis (Embden, Meyerhof and Parnas), respiration (Warburg), the 
tricarboxylic acid (TCA) and urea cycles (Krebs), glycogen catabolism (Cori and Cori), oxidative 
phosphorylation (OXPHOS) (Mitchell) and the importance of  adenosine triphosphate (ATP) in 
energy transfer reaction (Lipmann) (DeBerardinis and Thompson, 2012). At the end of this 
period, it was possible to understand at the level of enzymatic control such complex matters as 
the temporal organ-specific regulation of fuel preferences (Krebs, 1972).  
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Metabolic research has been driven by the realization that metabolic alterations accompany 
common human diseases. The research on the genetic and molecular bases of human 
diseases such as obesity, diabetes, neurodegeneration and cancer, triggered the attention in 
order to understand the altered metabolism states in these diseases. Several studies have 
come to reveal numerous regulatory mechanism that link cell signalling and the countless 
metabolic pathways, or enable cells to sense fuel availability and transmit the information 
through signalling networks (Bungard et al., 2010; Mathupala et al., 2006; Zaidi et al., 2012). 
Extracellular ligands can promote growth in most mammalian cells. These growth factors 
stimulate signal transduction pathways such as the phosphatidylinositol 3-kinase (PI3K)/Akt/ 
mammalian target of rapamycin (mTOR) pathway. The PI3K/Akt/mTOR stimulates both a rapid 
increase in essential nutrient uptake and the proper allocation of the nutrients into anabolic and 
catabolic pathways needed for macromolecules synthesis and energy production (Gibbons et 
al., 2009). The balance between anabolism and catabolism is dynamically regulated by the 
cellular energy status.  
The PI3/Akt/mTOR pathway promotes anabolism and suppresses catabolism (Figure 2), 
whereas the AMP-activated protein kinase (AMPK) does the reverse. This serine-threonine 
kinase is a “fuel sensor” activated during compromised bioenergetic states such as hypoxia 
and nutrient deprivation (Hardie, 2011). AMPK has also an important role in the regulation of 
p53 dependent cell-cycle checkpoint activated by glucose deprivation in cultured cells, limiting 
growth in energetically unfavourable states (Jones et al., 2005). AMPK also coordinates the 
expression of stress response genes through chromatin binding and histone H2B 
phosphorylation on serine 36, facilitating  AMPKs effect on gene expression (Bungard et al., 
2010).  
Metabolism also affects cell signalling by providing substrates for post-translational 
modifications (PTMs) that can modulate protein localization, trafficking and enzyme activity 
(Metallo and Heiden, 2010). ATP is the most obvious example, which provides the substrate 
for phosphorylation. This PTM can signal states of nutrient abundance because, in order to 
generate sufficient quantities of the required metabolite for protein modifications, requires 
access to nutrients in excess of the levels needed to run basic bioenergetics programs. Glucose 
and glutamine serve as the two primary carbon sources in proliferating cells, and uptake of 
both nutrients is directed by growth factor signalling. These nutrients also collaborate in another 
biochemical pathway to produce hexosamines, which modify nutrient transporters and growth 
factor receptors enabling their expression on the cell membrane. Glucose metabolism through 
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the hexosamine biosynthetic pathway is required to sustain sufficient growth factor signalling 
(Wellen et al., 2010). 
1.2  Metabolic alterations in cancer 
The metabolic proprieties of cancer cells are different from those of normal cells. Altered 
metabolism is one of the hallmarks of cancer cells (Hanahan and Weinberg, 2011; Máximo et 
al., 2009; Warburg, 1956). The chronic and often uncontrolled cell proliferation represents the 
essence of cancer cells involving deregulated control of cell proliferation and changes in energy 
metabolism in order to fuel cell growth and division. Under aerobic conditions, normal cells 
process glucose, first to pyruvate via glycolysis in the cytosol and thereafter to carbon dioxide 
(CO2) in the mitochondria; on the other hand, under anaerobic conditions, glycolysis is favoured 
and relatively little pyruvate is dispatched to the oxygen-consuming mitochondria (Hanahan 
and Weinberg, 2011). 
Otto Warburg first observed an anomalous characteristic of cancer cell energy metabolism 
(Warburg, 1956); even in the presence of oxygen, cancer cells can reprogram their glucose 
metabolism and thus their energy production, by limiting their energy metabolism largely to 
glycolysis, leading to a state that has been defined “aerobic glycolysis”. Also, Warburg 
hypothesized that this altered metabolism arose from mitochondrial defects that inhibit their 
ability to effectively oxidize glucose carbon to CO2. An extension of this hypothesis is that 
dysfunctional mitochondria could cause cancer (Koppenol et al., 2011). Indeed, many of the 
metabolism genes whose mutations can cause cancer are mitochondrial genes. Mutations in 
succinate dehydrogenase (SDH), an oxidoreductase complex that functions in electron 
transporter chain (ETC) and TCA cycle, were identified in dominantly inherited familial 
paraganglioma (Baysal, 2008), but also commonly found in gastric stromal tumours and 
childhood T-cell acute leukaemia (Baysal, 2007). Actually, loss-of function mutations in all the 
four subunits of the SDH complex have been identified in cancer (Baysal, 2008; Burnichon et 
al., 2010).  
Mutations in the TCA cycle enzyme fumarate hydratase (FH), that catalyses the reaction from 
fumarate to malate, have been identified in familial syndromes characterized by susceptibility 
to renal cell cancer and leiomyomatosis (smooth muscle tumours of the uterus and skin) 
(Tomlinson et al., 2002). Mutations in SDH and FH alter the complex II OXPHOS chain, which 
generates reduced flavine adenine dinucleotide (FADH2). There is some evidence that these 
mutations result in the inactivation of the prolpyl-hydroxylases (PHDs), leading to increases in 
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hypoxic induced factor-1 (HIF-1) and enhanced glycolysis. Based on these facts, both SDH 
and FH have been regarded as tumour suppressors.  
Other enzyme mutations may function as oncogenes, such as isocitrate dehydrogenase 1 and 
2 (IDH1 and IDH2). These mutations have been identified in gliomas and acute myelogenous 
leukaemia (AML) (Mardis et al., 2009; Parsons et al., 2008). These enzymes normally oxidize 
isocitrate to α-ketoglutarate (α-KG), with NADP+ reduced to NADPH in the process. IDH1 and 
IDH2 mutations result in a new ability of the enzyme to catalyse the NADH-dependent reduction 
of α-KG to 2-hydroxyglutarate (2-HG), an oncometabolite that can be a correlative marker for 
mutations occurring in isocitrate enzymes (Dang et al., 2010).    
Over the last decade, evidence has accumulated that the oncogenes Myc, nuclear factor kB 
(NF-kB), AKT, and the tyrosine kinase receptors (epidermal growth factor, EGF; insulin-like 
growth factor 1, IGF-1; human epidermal growth factor receptor, Her-2 etc), which turn on Ras, 
RAF-mitogen activated protein kinase (MAP- kinase), and the PI3K,  mTOR and HIF pathways, 
can stimulate the transcription of genes that encode proteins that mediate the glycolysis and 
glutaminolysis pathways. High AKT and mTOR activities result in high HIF activity. The Myc 
and HIF transcriptional factors increase the rate of some of the glucose transporters (GLUTs) 
and hexokinase II, enhancing both glucose uptake and its retention in the cell (Christofk et al., 
2008; Levine and Puzio-Kuter, 2010).  HIF increases the rate of transcription of several genes, 
resulting in angiogenesis, cell migration, cell survival, and energy metabolism (Levine and 
Puzio-Kuter, 2010).  
Hypoxia stress is a common phenomenon in tumour tissues and the predominant regulatory 
factor in the curse of hypoxia response is HIF.  When cells have adequate access to oxygen, 
HIF transcriptional activity is constrained through the constitutive degradation of HIFα by the 
von Hipple-Lindau (VHL)-mediated ubiquitination pathway. For this reaction, the proline 
residues of HIFα need to be hydroxylated before HIFα could be recognized by VHL. The 
hydroxylation of HIFα is catalysed by PDHs, a family of α-KG-dependent enzymes (Chen and 
Costa, 2009). HIF target genes, include genes encoding GLUTs and glycolysis enzymes such 
as pyruvate dehydrogenase kinase (PDK), lactate dehydrogenase A (LDH-A) and Myc. The 
loss of PTEN (phosphate and tensin homolog, a tumour suppressor gene) and concurrent 
increase of AKT-1 and mTOR, lead to HIF activation and the Warburg effect.  
The amplification of the oncogene Myc is universal in tumours arising from different tissues and 
organs and promotes mitochondrial utilization of glutamine by enhancing the expression of 
glutaminase (GLS) (Figure 2), which deaminates glutamine to glutamate (Dang, 1999; 
DeBerardinis et al., 2007; Vousden and Ryan, 2009).  
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P53 is one of the most important tumour suppressor protein and plays significant roles in normal 
cell functions. Either p53 mutations or depletion are associated with different types of cancer. 
Loss of p53 function also leads to Warburg effect, due to the repression of GLUT1 and GLUT4 
transcription (Dang, 1999; Vousden and Ryan, 2009).  
The p53 protein induces the transcription of TP53-inducible regulator of glycolysis and 
apoptosis (TIGAR) gene, which lowers the intracellular concentrations of fructose 2,6 
bisphosphatase (FBP) and thus decreases glycolysis by diverting glucose to the pentose 
phosphate pathway (PPP) (Figure 2) (Bensaad et al., 2006). The p53 protein enhance the 
transcription of the gene for synthesis of cytochrome c oxidase 2 (SCO2) (Figure 2), which, 
along with synthesis of cytochrome c oxidase 1 (SCO1), assembles into oxidative 
phosphorylation complexes. Cells with mutant p53 have compromised oxidative 
phosphorylation chain. P53 also promotes the synthesis of a number of proteins that reduce 
the high reactive oxygen species (ROS) load in cells, and inhibits the activity of the PI3K/AKT 
and mTOR pathways (Feng, 2010; Matoba et al., 2006).  
Pyruvate kinase (PK) is a glycolic enzyme that converts phosphoenolpyruvate (PEP) to 
pyruvate, with concomitant generation of ATP (Figure 2). There are four isoforms of PK, and 
its distribution in tissues and organs in human have certain specificities. PK isoform 1 (PKM1) 
is found in most adult tissues, the expression of PK isoform 2 (PKM2) is specifically related to 
development, mainly detected in embryonic cells and rapid dividing cells. In transformed cells 
PKM2 is de novo expressed and is thought to be associated with tumour growth. In recent 
years, increasing number of evidence showed that PKM2 expression is tumorigenic (Christofk 
et al., 2008). Nevertheless, this concept was challenged recently by a mass spectrometry 
quantification of PKM1 and PKM2 isoforms in malignant and normal tissues. PKM2 was indeed 
the prominent isoform in all cancer samples. However, it was also the predominant PK isoform 
in matched control tissues, such as unaffected kidney, lung, liver and thyroid. Thus, an 
exchange in PKM1 to PKM2 isoform expression during cancer formation may not be occurring 
in all types of cancer (Bluemlein et al., 2011). The outcome of having predominant PKM2 in 
cancer cells will directly restrain the production of pyruvate and lead to an increase of metabolic 
intermediates produced in the stage of glycolysis.  
The accumulation of the glycolytic products can be rescued for the biosynthesis of nucleotide, 
cholesterol, fatty acids, and other components required for cell proliferation and division 
through PPP and other synthetic pathway (Christofk et al., 2008).  
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Figure 2. Signalling networks and their regulation of metabolism in proliferating cells. The figure show aspects of 
metabolism in proliferating cells including glycolysis; lactate production; TCA cycle; oxidative phosphorylation (OXPHOS); pentose 
phosphate pathway (PPP); glutaminolysis; and the biosynthesis of nucleotides, lipids, and amino acids. PI3K/Akt signalling 
downstream of the receptor tyrosine kinase (RTK) activation increases glucose uptake through the glucose transporter (GLUT1), 
and increases flux through glycolysis. mTOR promotes protein synthesis and mitochondrial metabolism Glucose can be processed 
through glycolysis for the production of ATP and pyruvate, pass through the PPP to generate ribose 5-phospate and NADPH, and 
also enter the mitochondrial-localized TCA cycle. P53 induces TP53-inducible regulator of glycolysis and apoptosis protein 
(TIGAR), and represses the glucose transporters GLUT1 and GLUT4.  P53 enhaces the transcription of the gene for synthesis of 
cytochrome C oxidase 2 (SCO2) enhances mitochondrial respiration. Myc increases glutamine uptake and the conversion of 
glutamine into a mitochondrial carbon source by promoting the expression of the enzyme glutaminase (GLS); ACL indicates ATP 
citrate lyase; IDH, isocitrate dehydrogenase; PKM, pyruvate kinase isoforms 1 and 2; PFK, 6-phosphofructo-1-kinase; FBP, 
fructose 1,6bisphosphsate; α-KG, alpha ketoglutarate; NADPH, reduced nicotinamide adenine dinucleotide phosphate; PEP, 
phosphoenolpyruvate (Adapted from Gerhäuser, 2012). 
1.3 Mitochondrial genome and the role of mtDNA in the pathogenesis of mitochondrial 
dysfunction in cancer 
Mitochondria have a central role in energy uptake and energy production, and as consequence 
plays a key role in a wide variety of both pathological conditions, such as cancer 
neurodegenerative diseases, diabetes and aging and non-pathological (heat production, ROS 
generation, apoptotic and cellular differentiation) conditions. Several studies have focused their 
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attention on the influence of variability of mitochondrial DNA (mtDNA) on the abovementioned 
aspects (Wallace, 2010).   
The mtDNA represents less than 1% of the total cellular DNA. However, its mitochondria gene 
products are essential for normal cellular function. Mitochondrial DNA within a single cell 
generally has identical sequences which are described as homoplastic. Heteroplasmy or 
different mtDNA sequences within mitochondria of the same cell can occur in response to 
somatic mutations. (Chatterjee et al., 2006; Minocherhomji et al., 2012).  
The human mitochondrial genome is a 16.6kb circular DNA encoding for 13 proteins of the 
OXPHOS and the displacement loop (D-Loop), as well as 22 tRNAs and 2 rRNAs necessary 
for the translation of mitochondrial genes within mitochondrion. The D-Loop is a non-coding 
region within mtDNA contains cis-acting regulatory elements that are required for replication 
and transcription of mtDNA. All others mitochondrial proteins, including those involve in the 
replication and transcription of mtDNA are nuclear-encoded. Nuclear encoded proteins are 
imported by specialized complexes on the inner and outer mitochondrial membrane 
(Minocherhomji et al., 2012; Wallace and Fan, 2010).  
MtDNA variants define specific mtDNA haplotypes. Haplotypes with a common phylogenetic 
origin are categorized into haplogroups which display a continent-specific distribution. The 
mtDNA of the European population falls within nine different haplogroups (H, J, U, X, T, I, K, W 
and V) as identified by (Torroni et al., 1996) 
The mtDNA haplogroups were initially considered as being neutral and used only for phylogeny 
analysis and population studies. However, several studies revealed the importance of mtDNA 
variants in quality of aging and the susceptibility to late-onset pathologies, such as cancer, 
diabetes, cardiovascular and neurodegenerative disease (Fang et al., 2010; Santoro et al., 
2006; Takasaki, 2009). It has been widely reported that mtDNA molecules belonging to different 
haplogroups may differ in degree of OXPHOS activity, and in turn, results in different 
percentages of oxygen consumption, ATP and mitochondrial ROS production or heat 
generation (Marcuello et al., 2009; Pello et al., 2008). Nevertheless there is also evidence that 
different mtDNA haplogroups may maintain similar efficiency in OXPHOS performance through 
the fine-tuning of ROS production and mitochondrial biogenesis. It has also been proposed that 
variants which alter OXPHOS coupling efficiency, thus less ATP and more heat production, are 
more frequent in cold areas (Elson et al., 2007).  
Depletion of mtDNA content as well as inherited mutations in mtDNA has been reported in a 
variety of diseases including cancer. Somatic mutations in the D-Loop region have been 
identified in several tumours. Since the D-Loop region contain regulatory elements involved in 
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mtDNA replication, it could affect the mtDNA copy number. Indeed tumour-specific changes in 
the mtDNA copy number have been reported in human cancer (Kulawiec et al., 2009; Tseng 
et al., 2006). Additionally, mtDNA dimers and mtDNA mutations have been found in patients 
with leukaemia, hepatocellular carcinoma, renal cell carcinoma, lung cancer, breast cancer, 
thyroid cancer, ovarian cancer, among others (Chandra and Singh, 2011; Máximo et al., 2002; 
Modica-Napolitano and Singh, 2004). Most pathogenic mtDNA mutations induces defects in 
OXPHOS. 
More recently, cells devoid of functional mitochondrial (Rho0 cells) are been used in studies 
aiming to gain insight into the possible role of mitochondria in regulating or being associated 
with epigenetic alterations of the nuclear genome, either gene specific or genome wide 
(Minocherhomji et al., 2012). Additionally, several studies have been reporting that 
mitochondrial dysfunction induces changes in the expression of nuclear genes involved in 
metabolism, cell signalling, growth, differentiation and apoptosis (Delsite et al., 2002). 
1.4 Metabolism and epigenetics 
A regulated cross-talk between metabolic pathways in the mitochondria and the epigenetic 
mechanism in the nucleus allows cellular adaptations to new environmental conditions. The 
term "epigenetics" originally defined by Waddington as "the causal interactions between genes 
and their products, which bring the phenotype into being" involves the understanding of 
chromatin structure and its impact on gene function (Waddington, 1942). Currently, epigenetic 
might be defined as modifications of the DNA or associated proteins, other than DNA sequence 
variation itself, that carry information content during cell division (Sharma et al., 2010). In 
addition to primary DNA sequence information, much of the information, regarding when and 
where to initiate transcription, is stored in covalent modifications of DNA and its associated 
proteins. The pattern of various modifications along the chromatin, such as DNA cytosine 
methylation and hydroxymethylation, acetylation, methylation, phosphorylation, ubiquitination, 
and SUMOylation of the lysine (K) and/or arginine (R) resides of histones are thought to 
determinate the genome accessibility to transcriptional machinery. An emerged concept is that 
information about a cell’s metabolic state is also integrated into the regulation of epigenetics 
and transcription (Figure 3) (Ward and Thompson, 2012). 
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Figure 3. Signalling and metabolic inputs into epigenetics Growth factors, hormones and cytokines activate the classic 
signalling pathways and downstream transcriptional factors which recruit chromatin-modifying enzymes to local chromatin. The 
nutrient levels and cell metabolism will affect levels of the metabolites which are required substrates of chromatin-modifying 
enzymes that use these metabolites to post-translationally modify both histones and DNA (Lu and Thompson, 2012). 
It is now appreciated that cells constantly adjust their metabolic state in response to 
extracellular signalling and/or nutrient availability (Vander Heiden et al., 2009). Most of the 
cellular signalling events are dictated by growth factors, cytokines or hormones, but metabolism 
still plays a significant role in transcription. This also has a potentially fusing logic, as most 
chromatin-modifying enzymes requires substrates or co-factors that are derived from various 
metabolic pathways, including glycolysis, fatty acid oxidation TCA cycle and OXPHOS 
(Teperino et al., 2010). The fluctuation of metabolite levels can modulate the activities of 
chromatin dynamics (Figure 4). As many complex diseases such as cancer and type II diabetes 
display abnormalities of cellular metabolism and epigenome, understanding the molecular 
connections between these processes may have therapeutic implications.   
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Figure 4. Crosstalk between metabolism and epigenetics.  As glucose enters the glycolytic pathway, minor portion is branched 
to hexosamine biosynthetic pathway to produce GlcNAc which can be used as substrate for histone GlcNAcylation by GlcNAc 
transferases (OGT), oxidative phosphorylation (OXPHOS) determines the NAD+/NADH ratio which is important for the activities of 
Sirtuins. Several TCA cycle intermediates can be exported out of the mitochondria including citrate and alpha-ketoglutarate (α-
KG). Cytosolic citrate is converted to acetyl-CoA which is used as a donor for histoneacetyltransferases (HAT) – mediated histone 
acetylation. α-KG is used as co-factor for histone and DNA demethylation reactions by Jumonji-C domain containing histone 
demethylases (JHDM) and ten-eleven translocation protein (TET), respectively. The substrate for histone methyltransferases and 
DNA methyltransferases (DNMT) is S-adenosylmethionine (SAM), which is synthesized from essential amino acid methionine. The 
lower ATP/AMP ratio can activate AMP-activated protein kinase (AMPK), a kinase that phosphorylates histones (Adapted from Lu 
and Thompson, 2012). 
1.5 Protein post-translational modifications and cell signal transduction 
Post-translational modification of proteins is a more efficient way to regulate cellular functions 
than gene transcription for animals and humans to adapt to different physiological and 
environmental conditions (Wang et al., 2013). In spite of the regulatory power garnered by 
protein kinase, other reversible protein PTMs are increasingly becoming appreciated as having 
important roles in cell signal transduction (Deribe et al., 2010). These modifications include 
protein acetylation, methylation, O-linked glcNAcylation, ADPribosylation, and many others; 
many of these modifications are conserved down to the level of prokaryotes (Figure 4) 
(Locasale and Cantley, 2011; Walsh et al., 2005)  
Current estimates from advances in mass spectrometry-based proteomics suggest that many 
of these modifications may be as prevalent in mammalian systems as the more studied 
phosphorylation. In contrast to reversible protein phosphorylation, each of these modifications 
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is carried out by a relatively small number of enzymes. The number of distinct 
acetyltransferases, methytransferases, GlcNAc transferases, ADP-ribosyltransferases, etc., is 
much smaller than the total number of unique protein kinases (Locasale and Cantley, 2011). 
Also, in contrast to the case of protein kinases, where physiological concentrations of the 
substrate ATP far exceed the Michaelis constant, the enzymes that carry out these 
modifications typically have Michaelis constants for their metabolic substrates that are close to 
the physiological concentrations. These substrates include acetyl-Coenzyme A (Acetyl-CoA), 
S-adenosylmethionine (SAM), N-acetylglucosamine, and adenosine diphosphate -ribose 
(ADP-ribose), and their levels are dynamically regulated by alterations in cellular metabolism. 
Changes in these concentrations can result from variations in metabolic flux occurring from 
countless mechanisms such as changes in nutrient uptake and/or mutations in metabolic 
enzymes. These changes can affect their concentrations by several orders of magnitude and 
in turn affect activity of their corresponding enzymes by shifting the substrate concentration to 
levels well above or below the Michaelis constant of the enzymes. Therefore, the diversity of 
signalling responses regulated through these modifications may have evolved from the ability 
of metabolic networks to adapt metabolism to achieve differing levels of substrate availability. 
These forms of signal transduction are more ancient than protein kinases and have evolved 
from more primitive versions of signal transduction observed in lower organisms (Locasale and 
Cantley, 2011). 
1.6 DNA methylation - 5-methylcytosines (5-mC)  and 5-hydroxymethylcytosine (5-hmC) 
Methylation of DNA at the carbon 5 of cytosine residues that precede guanines (referred to as 
CpG dinucleotides) is the most studied and best-known epigenetic modification. Alterations in 
the pattern of nuclear DNA methylation, such as hypomethylation of the repetitive elements 
associated with increased genomic instability, are frequently seen. The hypermethylation of 
specific GpG island in the promoter regions of several tumour-suppressor genes is commonly 
observed to be associated with transcriptional silencing of the gene (Sharma et al., 2010). DNA 
methylation is established by a family of proteins called DNA methyltransferases (DNMTs). 
Three active DNMTs have been described in mammals: DNMT1, DNMT3A and DNMT3B. 
DNMT1 exhibit great preference for hemimethylated DNA and, therefore, is responsible for 
maintaining methylation pattern after DNA replication. DNMT3A and DNMT3B are the de novo 
methyltransferases, because they can establish the DNA methylation pattern, although they 
show equal preference for unmethylated or hemimethylated DNA (Robertson, 2001). A third 
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homologue of this family, DNMT3L, lack the methyltransferase capacity but is known to assist 
the other members of the family in methylation reactions by interacting with their catalytic 
domains (Gowher et al., 2005). DNMTs transfer a methyl group from SAM to the substrate with 
the formation of the by-product S-adenosylhomocysteine (SAH). The altered redox state of 
cancer cells influence SAM levels through aberrant regulation of the methionine cycle. SAM is 
derived from the essential amino acid methionine through methionine adenosyltransferase 
(MAT) by combining methionine with ATP (Cai et al., 1996). SAM reactions included in one-
carbon metabolism are coupled to polyamine synthesis and to the folate cycle. SAM is also a 
precursor of important metabolites like glutathione, through transsulfuration reactions 
(Huidobro et al., 2013). The nomenclature used to describe MAT enzymes can be confusing. 
There are three major multimeric MAT enzymes: MATI, MATII, and MATIII (Mato et al., 2002). 
MATI is a tetramer and MATIII is a dimer of the protein encoded by methionine 
adenosyltransferase I alpha (MAT1A), the “hepatic form” of the enzyme (Lu and Mato, 2005). 
In contrast, MATII is a dimer of the protein encoded by methionine adenosyltransferase II alpha 
(MAT2A) and is expressed in most extra hepatic tissues. A third gene, methionine 
adenosyltransferase II beta (MAT2B), unrelated in amino acid sequence to MAT1A or MAT2A, 
encodes a regulatory subunit that physically associates with the MAT2A dimer, forming a 
heterotetramer (Martínez-Chantar et al., 2003). 
The enzyme glycine N-methyltransferase (GNMT) catalyses the SAM-dependent methylation 
of glycine to form sarcosine. Kerr suggested a role for GNMT in regulating the relative levels of 
SAM and SAH (Kerr, 1972). It is important to realize that SAM is the methyl donor for almost 
all cellular methylation reactions and therefore GNMT is likely to regulate cellular methylation 
capacity. In addition, GNMT has been proposed to link the de novo synthesis of methyl groups 
to the ratio of SAM to SAH, which in turn serves as a bridge between methionine and one-
carbon metabolism (Figure 5) (Luka et al., 2009).  
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Figure 5. Schematic illustration of  one-carbon metabolism. MAT indicates methionine adenosyltransferase; SAM, S-adenosyl-
methionine; SAH S-adenosyl-homocysteine; DNMT, DNA methyltransferases; R methyl group acceptors; MS methionine 
synthase; GNMT glycine N-methyltransferase (Adapted from Huidobro et al., 2013). 
A covalent methyl group is chemically stable. Therefore DNA methylation was considered as a 
relative static epigenetic mark. However during embryonic development there is extensive 
remodelling of the cellular methylome, suggesting the existence of enzymes that actively 
remove methylation marks. The ten-eleven translocation protein (TET) family members- TET1, 
TET2 and TET3 – are an α-KG and Fe (II)-dependent dioxygenase that hydroxylate the  5-mC 
of DNA to 5-hmC, utilizes α-KG, oxygen and Fe (II) as co-factors and releases succinate as 
by-product. Succinate and fumarate are inhibitors of TET enzymes. The function of 5-hmC is 
the topic of intense investigation and thought to serve as an intermediate for subsequent active 
(TET-dependent) or passive (replication-dependent) demethylation. From the metabolic 
perspective the demethylation mechanism by TET is interesting as it involves α-KG and 
succinate, key metabolites of the TCA cycle. Because of the dependency in key metabolites 
the rate of demethylation could be regulated at both levels of co-factor availability and feedback 
inhibition. 
1.7 Acetyl-CoA and metabolism  
The ancient energy precursor of metazoan metabolism is acetate. The main sources of cellular 
acetate are the mitochondrial processes of glucose-derived pyruvate oxidation, the oxidation 
of fatty acids and the amino acid catabolism (Wagner and Payne, 2011). These distinct 
metabolic pathways are all capable of yielding the activated form of cellular acetate, or acetyl-
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CoA. How mitochondrial acetyl-CoA is used throughout the cell is heavily dependent on the cell 
type and the metabolic state of the organism. However, the primary function of acetyl-CoA 
throughout all cell types is to serve as a carbon donor in the TCA cycle. In general, during a 
state of nutrient excess, a proportion of the excess acetyl-CoA generated within the 
mitochondria is exported to the cytosol in the form of citrate, where it is reconverted into acetyl-
CoA by ATP-citrate lyase (ACL) (Figure 6). 
In normal cells, it is possible that ACL becomes phosphorylated in response to growth factor 
dependent AKT activation, transiently stimulating acetyl-CoA production. However, in cancer 
cells, in which the PI3K/AKT pathway is constitutively active, ACL might become continuously 
active, allowing high levels of acetyl-CoA production even if the nutrient availability becomes 
limited (Biology and Mazurek, 2011). This would provide continuous acetyl-CoA and modulates 
metabolism in a growth promoting manner (for example by stimulating PKM2 degradation, 
which increases the availability of glycolytic intermediates for use in biosynthetic pathways) 
(Wellen and Thompson, 2012). Free cytoplasmic and mitochondrial acetate can also be 
converted into acetyl-CoA via an ATP-dependent mechanism by acetyl-CoA synthetase 1 
(AceCS1) and 2 (AceCS2), respectively. The cytosolic acetyl-CoA is essential for the 
production of fatty acids and sterol, which are vitally important for the formation and 
maintenance of lipid membrane and protein acetylation, including histone acetylation in the 
nucleus (Wagner and Payne, 2011; Wallace and Fan, 2010; Wellen et al., 2009). The acetyl-
CoA groups used to modify histones are predominantly produced by ACL (Figure 6). Loss of 
function of this enzyme reduces histone acetylation, with global consequences on gene 
expression (Wellen et al., 2009).  
In cancer cells aerobic glycolysis is elevated and this improved glucose catabolism results in 
an excess of the glycolytic end product-pyruvate, and although most of the pyruvate is 
converted into lactate and secreted out of the cells, part of the pyruvate enters in the 
mitochondria, where it is decarboxylated into acetyl-CoA by pyruvate dehydrogenase (PDH) 
(Zaidi et al., 2012). The mitochondrial acetyl-CoA combines with oxaloacetate (OAA) by the 
citrate synthase 2 generating citrate that enters the TCA cycle (Macdonald et al., 2011). In this 
step mitochondrial citrate can also be exported to the cytosol to be used as biosynthetic 
precursor for lipogenic pathways to support the highly demanding proliferating cells. The 
withdrawal of citrate exported to the cytoplasm may stop the TCA cycle unless additional 
pathways are engaged to supply OAA to keep the cycle going. Henceforth, a constant supply 
of OAA is crucial for cancer cells. Although many cancer cells use glutamine metabolism for 
anaplerotic supply of OAA, some cancer cells use a compensatory anaplerotic mechanism in 
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which pyruvate is carboxylated to form OAA in a reaction catalysed by pyruvate carboxylase 
(Cheng et al., 2011).  
 
Figure 6. Role of acetyl-CoA in protein modification and growth. Acetylation serve as indicator of nutrient sufficiency to the 
cell to signal that conditions are optimal for growth. Nutrient-sensitive acetylation of histones (and other transcriptional regulators) 
can regulate the expression of genes involved in cell growth. ACL indicates ATP citrate lyase; GF growth factor; GFR growth factor 
receptor; PEP phosphoenolpyruvate; F6P fructose 6 phosphate (Adapted from Wellen and Thompson, 2012). 
For a long time it was thought that glucose metabolism was the main source of citrate for the 
downstream pathways. However recent studies report that, in tumour cells with mitochondrial 
dysfunction or in proliferating cells under hypoxic conditions, reductive carboxylation of 
glutamine-derived α-KG is responsible for supplying citrate for de novo lipogenesis (Cheng et 
al., 2011). This pathway uses IDH1 and IDH2, cytosolic and mitochondria IDH isoforms, 
respectively (Zaidi et al., 2012).  
The acetylation process is regulated in a complex manner through several mechanisms partly 
including metabolism. The acetyl-CoA production itself probably represents an integration of 
nutrient and signalling cues. As mentioned above, citrate availability regulates the production 
acetyl-CoA by ACL, but ACL activity itself can be regulated by phosphorylation of ACL at 
Ser454, a target of both AKT and cAMP-dependent protein kinase (PKA), that increases its 
activity even at lower levels of citrate (Berwick et al., 2002; Sale et al., 2006; Wellen et al., 
2009).  
 
 
 
18 
 
1.8 Lysine acetylation and mitochondria 
All over the time, the eukaryotic organism developed fine adapted metabolic mechanism for 
coordinating the conversion of diverse carbon substrate into cellular energy. These 
mechanisms include changes in gene transcription, allosteric regulation of metabolic enzymes 
by the flux of intermediary metabolites and direct regulation by PTMs. 
Protein lysine acetylation was first discovered almost 50 years ago on nuclear histones, but the 
broad involvement of this reversible covalent modification in cell regulation has only been 
appreciated during the last decade. Diverse proteins functions are generated by means of their 
PTMs. These PTMs are used to generate and transmit chemical signals across diverse cellular 
pathways. As well as protein phosphorylation, acetylation of specific lysine residues can have 
numerous functional consequences including enzyme activation/inactivation, changes in 
protein–DNA interaction, protein stability, subcellular localization and specific functional 
complex formation (e.g. protein–protein interaction). Several studies have shown that the 
dynamic acetylation at the epsilon-amino group (ε-amino group) of a lysine residue can target 
key enzymes, modulate the activity of mitochondria-localized fatty acid  β-oxidation, the TCA 
cycle, urea cycle, and OXPHOS in a nutrient responsive manner. The enzymes that catalyse 
the reversible acetylation of proteins are the protein lysine acetyltransferases (KATs, formerly 
termed histone acetyltransferases, HATs) and deacetylases (KDAC) (commonly known as 
histone deacetylases, or HDACs). There are three major families of HATs: general control non-
derepressible 5 (Gcn5)-related N-acetyltransferases (GNATs), p300/CBP and MYST proteins 
(Sterner and Berger, 2000; Yang and Seto, 2007). p300 (adenoviral E1A-associated protein of 
300 kDa) and CBP (CREB-binding protein) form a pair of paralogous transcriptional co-
activators (Goodman and Smolik, 2000). The KDACs are divided into classes I,II and IV and 
the Sirtuin family (also known as class III KDACs) (Patel et al., 2011). 
The reversible and nutrient-sensitive manner of many of these acetyl modifications has strongly 
implicated the mitochondrial-localized members of the NAD+-dependent deacetylases 
(Sirtuins) as regulatory mediators of these fundamental metabolic processes. Alterations in 
Sirtuins activity are also associated with the development of age-related conditions such as 
neurodegenerative disease, heart disease, and cancer.  
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1.9 Protein acetylation and Sirtuins  
Conserved from bacteria to mammals, the Sirtuins are a protein family involved in the  
regulating of many biological processes, including metabolism of fat and glucose related to 
physiological changes in the energy or ROS levels, development and longevity (Haigis and 
Sinclair, 2010; Houtkooper et al., 2012). Sirtuins modify proteins through lysine deacetylation 
and ADP-ribosyltransferase activity, both requiring NAD+ as an obligate co-factor. Since the 
NAD+ levels ride in response to reduced energy status and/or altered redox, Sirtuins provide a 
mean by sense and response to the environment (Guan and Xiong, 2011). Sirtuins activity can 
be repressed by NADH and by the product of the Sirtuin deacetylase reaction, nicotinamide 
(NAM) (Bitterman et al., 2002; Lin et al., 2004). 
There are seven Sirtuins (Sirt1-Sirt7) in mammals that are different in their tissue specificity, 
sub-cellular localization, enzymatic activity and targets. Sirt1 has been related to contribute to 
the anti-aging effect of caloric restriction (CR) through the modulation of mitochondrial function. 
Several targets have been described for Sirt1 in the regulation of mitochondria function, Sirt1 
can promote the biogenesis of mitochondria by activation of peroxisome proliferator-activated 
receptor gamma co-activator 1-alpha (PGC-1α), increase the oxidative metabolism via 
repression of HIF-1α-dependent transcription of several genes, and decrease of ROS 
production through Foxo-dependent increase of the expression of antioxidant enzymes. A 
decrease in mitochondria-elicited ROS production and increase in the efficiency of 
mitochondrial OXPHOS contribute to the extension of lifespan in laboratory animals (Salminen 
et al., 2013). 
As mentioned above a large proportion of mitochondrial proteins are reversible regulated by 
acetylation and deacetylation, and the acetylation levels are sensitive to metabolic states and 
dietary conditions. There are three Sirtuins (Sirt3, Sirt4 and Sirt5) located in the mitochondria. 
Sirt3 is the major one that regulates the global acetylation of proteins in mitochondria. Sirt3-
dependent deacetylation regulates the activity of AceCS2 which catalyzes the conversion of 
acetate to acetyl-CoA. Sirt3 play an essential  role  in regulation of enzymes that are involved 
in antioxidant defence such as IDH2, an enzyme of TCA cycle, responsible for the replenish 
NADPH pool in mitochondria (Someya et al., 2010), and regulates the deacetylation and 
activation of manganese superoxide dismutase (MnSOD) (MnSOD can be acetylated at least 
in four lysine’s residues k53, k68, k89, k122). The MnSOD is one of the primary mitochondrial 
antioxidant in a network of detoxification enzymes that neutralizes the highly reactive 
superoxide ions (O2•¯ ) to less reactive hydrogen peroxide (H2O2) followed by its immediate 
conversion to H2O by catalase and other peroxidases in the mitochondrial matrix (Oberley and 
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Oberley, 1988). Some authors have been shown lysines 53, 68, 89 and 122 as acetylation 
targets that are directly related with enzymatic function (Chen et al., 2011; Qiu et al., 2010; Tao 
et al., 2012). MnSOD and IDH2 represent Sirt3 targets that directly regulate mitochondrial ROS. 
Moreover, Sirt3 has been shown to regulate mitochondrial OXPHOS by activation of Complex 
I (Ahn et al., 2008), II (Wallace et al., 2011) and V (Wu et al., 2013) in response to greater 
energy demand and prevent the opening of mitochondrial permeability transition pore (mPTP) 
by deacetylation of Cyclophilin D (Cyp D) on Lys166. Glutamate dehydrogenase (GDH) which 
can regulate glutamate oxidative stress and NADPH is also deacetylated by Sirt3. Several 
studies have emphasized a pivotal role for Sirt3 in cancer, even going far as referring to it as a 
tumour suppressor. However, the ability of Sirt3 to act as a tumour suppressor is directly related 
to its role in regulating ROS levels (Webster et al., 2012). 
Sirt3 appears to play a role in preventing the switch to the metabolic profile characteristic of 
cancer cells. The sirtuin-3-dependent deacetylation of Cyp D causes a detachment of 
hexokinase II from the mitochondria that is necessary for stimulation of OXPHOS, and also 
prevents hexokinase II from binding to voltage-dependent anion channel protein (VDA) and the 
mPTP, limiting its ability to use ATP and augment glycolysis (Mathupala et al., 2006; Shulga et 
al., 2010). 
1.10 Role of lysine acetylation in chromatin remodelling  
A simple model for the function of histone acetylation suggests that acetylation neutralizes the 
positive charge on lysine side chains and thereby reduces interaction with the negatively 
charged DNA backbone, allowing transcription factors to better access to the DNA (Dion et al., 
2005). The histone acetylation and its role in the regulation of transcription has long been a 
topic of research in cell and molecular biology. However several studies have revealed the role 
of histone acetylation in other important processes regulating the structure and function of 
chromatin, and hence, the eukaryotic genome (Dang et al., 2009; Donohoe et al., 2012; 
Rodríguez-Paredes and Esteller, 2011). 
The process of organizing the base pairs of genetic material in the eukaryotic nucleus has 
profound effects on DNA-dependent events, such as transcription, recombination, replication 
and repair. DNA is organized by its incorporation into chromatin, the basic subunit of chromatin 
being the nucleosome. The nucleosome is composed of 147 base pairs of DNA wound around 
an octamer containing two copies of each histones H2A, H2B, H3, and H4. Histone proteins 
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have N-terminal tails that can be modified in various ways, histones H3 and H4 being the best 
characterized (Böhm et al., 2011). 
The most widely studied histone modification is acetylation. Histones are covalently modified 
at the ε-amino group of conserved lysines by the HATs. The nuclear HATs acetylate histones 
in a manner associated with transcription and other DNA-dependent processes. Allfrey et al., 
(Allfrey et al., 1964) made the earliest observations linking histone acetylation to transcription. 
It is well recognized that there is a positive correlation between the degree of histone acetylation 
and transcriptional activity throughout the genome. On the other hand, the chromatin on 
transcriptionally inactive genes is mostly hypoacetylated (Offermann et al., 2008). The N-
terminal tail of histone H3 is primarily acetylated at lysines 9 (H3K9), 14 (H3K14), and 18 
(H3K18), while that of H4 is acetylated at lysines 5 (H4K5), 8 (H4K8), 12 (H4K12), and 16 
(H4K16). There are additional acetylation sites on both histones, but their significance and 
function are mostly unknown (Kurdistani et al., 2004; Zhang et al., 2007). Additionally, specific 
triggers might store information on genes in the form of histone modification patterns that are 
read out by transcription factors and/or the transcription machinery. Dependent on the crosstalk 
between individual modifications and the complexity of modification patterns, this signature is 
often referred to as a “histone code”(Jenuwein and Allis, 2001) or a “histone language” (Berger, 
2007).  
Considering the number of potential acetylation sites in each histone, the acetyl-CoA levels 
could be limiting, suggesting that changes in histone acetylation may influence acetyl-CoA 
metabolism. In this context, histone acetylation is a highly dynamic process, maintained by the 
alternate action of histone acetyltransferases and deacetylases, which activities are 
coordinated in a highly regulated fashion. Some studies report that alteration in the expression 
of HDACs, namely Sirt6, in cells, result in a high glycolysis rate and low TCA cycle activity.  
Part of the mechanism is clearly transcription-dependent: Sirt6 deacetylation of H3K9 at the 
promoters of glycolytic genes is required to slow down the expression of these genes. However, 
it is emblematic how the absence of an HDAC has such a profound impact on the TCA cycle, 
a pathway that relies directly on acetyl-CoA availability (Cantó et al., 2013; Martinez-Pastor et 
al., 2013).  
Under conditions of nutrient limitations, in which cells are forced to recycle citrate to replenish 
the acetyl-CoA pool, a decrease in citrate metabolism might result in reduced acetate/acetyl-
CoA availability. In this context, the changes in glycolytic gene transcription programs observed 
in  Sirt6 deficient cells may not only be a response to nutrient stress but may also represent an 
important adaptive mechanism against a limiting acetyl-CoA pool. Mitochondrial dysfunction, 
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by itself, might alter the acetyl-CoA levels, and the NAD+/NADH ratio through alterations in TCA 
cycle and OXPHOS have impact in the normal function of HAT and Sirtuins (Martinez-Pastor 
et al., 2013).  
1.11 Cybrids 
In 1989 for the first time, King and Attardi showed that Rho0 (mtDNA devoid) human cells can 
be repopulated with exogenous human mitochondria (King and Attardi, 1989). Cybrids are 
cytoplasmatic trans-mitochondrial hybrids that can be used to study the influence of mtDNA 
variations in nuclear epigenetics. The means to assess the phenotypic effects of mtDNA 
mutations are not the standard cloning/transfection methods used to study nuclear DNA genes, 
because the mitochondrial genome has its own genetic code and because it is not possible to 
make stable transfections directed to mtDNA. One way to circumscribe this problem is by using 
cybrids. These cybrid cell lines are obtained from the fusion of a recipient Rho0 cell line that is 
devoid of mitochondrial DNA and a donor cell line (that has to be removed of the nucleus but 
maintains mitochondria and mtDNA) that contains the mtDNA of interest (Figure 7).  
These technology allows the differentiation of the effects caused by mtDNA mutations from 
those caused by nDNA, since the cybrids cell lines have the same nuclear background 
(Swerdlow, 2007).  
 
Figure 7. Schematic representation of the cybrid production method. Starting from a cell line without mtDNA (but with 
mitochondria) and enucleated cell that contain the mtDNA of interest, it is possible to perform cell fusion resulting in cybrid line that 
harbours the mtDNA mutation in a varying degree of heteroplasmy. After culturing the cybrid cell line it is possible to obtain a 
homoplasmic wt or homoplasmic mutant mtDNA cell line and heteroplasmic cell line ( Adapted from Máximo et al., 2009). 
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2.1 Hypothesis  
"Mitochondrial dysfunction" due to mutations in mtDNA genes and mitochondrial variants, 
mediate epigenetic cellular changes and may play key roles in phenotypic variation related to 
mitochondrial diseases and cancer. 
2.2 Aim  
Having in mind the aforementioned observation and our hypothesis, we have developed a 
project with the following aim:   
To unveil how pathogenic mutations in mtDNA and/or mitochondrial variants may lead to 
epigenetic changes, namely alterations in the pattern of nuclear DNA methylation and/or 
acetylation of histones and other proteins. 
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3.1 Cell lines and cell culture conditions 
The 143B and 143B Rho0 are osteosarcoma-derived cell lines and were a kind gift from Dr. 
Keshav Singh (Roswell Park Cancer Institute, Buffalo USA). The 143B Rho0 is derived from 
the 143B cell line, after depletion of mtDNA, hence they share the same nuclear background. 
The 143B Rho0 cells were generated using herpes simplex virus (HSV), atransient expression 
of UL12.5, a protein encoded by the HSV UL12 gene with mitochondrial localization, leads to 
the degradation of mtDNA, through nuclease activity, leaving nuclear DNA intact. Mitochondrial 
mRNAs are also depleted as rapidly as the mtDNA, after HSV infection (Saffran et al., 2007). 
The cybrid cell lines, 3571Cy 1, 3571Cy 22, Cy 24, 3243Cy 9.7 and the CMPBR3 were 
previously established in our laboratory. Cybrid clones were constructed using three types of 
mitochondria donors: the cell line XTC.UC1, which harbours a mtDNA ND1 gene mutation (C 
insertion at 3571 position) and a mutation in the cytochrome b gene (missense substitution, 
E271K, 15557 G>A), resulting in three clones, two of them with a mtDNA ND1 gene mutation 
(3571Cy1 and 3571Cy 22) and a third clone with wild type mtDNA (Cy 24) (Bonora et al., 2006); 
platelets of a patient with the A3243T mutation in the mtDNA tRNALeu (UUR) gene (3243Cy 9.7); 
and platelets from a healthy individual (wild type mtDNA) (CMPBR3). The 143B Rho0 cell line 
was used, as mitochondria acceptor. All the cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) high-glucose supplemented with 10% (v/v) inactivated and filtered 
fetal bovine serum (FBS), 1% (v/v) penicillin/streptomycin (PenStrep), 0.5% fungizone and 
50µg/ml uridine. The cells were maintained at 37ºC, 5% CO2 in a humidified incubator and 
cultured as a monolayer. 
The media and FBS, used in the experiments, were purchased from PAA as part GE Healthcare 
(UK); Trypsin-EDTA, PenStrep and fungizone were purchased from GIBCO, as part of 
Invitrogen Life Technologies (Carlsbad, California). 
3.2 Nucleic acids extraction from cell lines 
3.2.1 DNA extraction  
Plated cells (70-80% confluence), were washed in PBS 1X (phosphate buffered saline), 
trypsinized (0.05% trypsin-EDTA), and pelleted (1200rpm, 5minutes). This procedure was 
performed using Invisorb Spin Tissue Mini Kit. The process was done according to the 
manufacturer’s instructions (Invisorb Spin Tissue Mini Kit, Invitek, Berlin, Germany) for DNA 
isolation from 10-106 eukaryotic cells/cell pellets. 
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DNA was quantified using NanoDrop ND-1000 Spectrophometer (Nanodrop Technologies, 
Inc., Delaware, USA) and DNase/RNase (GIBCO, Invitrogen, Carlsbad, CA, USA) free distilled 
water as blank.  
3.2.2 RNA extraction  
For RNA extraction, 1ml of TRIZOL reagent (Life Technologies TM, California, USA), was added 
directly to the cell pellets previously washed twice in PBS 1X buffer. The remaining protocol 
was performed according to manufacturer’s instructions (TRIZOL Reagent, Life 
TechnologiesTM ,California, USA). RNA concentrations were determined using the NanoDrop 
ND-1000 Spectrophometer (Nanodrop Technologies, Inc., Delaware, USA) and DNase/RNase 
(GIBCO, Invitrogen, Carlsbad, CA, USA) free distilled water as blank. 
3.3 Polymerase Chain Reaction (PCR) 
Since the primers available for ND1 gene amplification, include the region where the mutation 
A3243T of the mtDNA tRNA Leu (UUR) gene is located, they were used to monitor both mutations. 
Additionally in order to confirm the sequences of the cell lines, PCR and DNA sequence were 
performed to confirm the absence of mutations in the 143B, CMPBR3, Cy 24 and 143B Rho0 
cell lines using the following conditions:  
PCR reactions were performed using ~100ng of genomic DNA extracted from cell lines, 0.1µM 
of each forward and reverse primers (Invitrogen, UK), 1x PCR Buffer (5x GoTaq Flexi Buffer, 
Promega, WI, USA), 1.5mM of Magnesium Chloride solution (Promega WI, USA) 40mM 
deoxyribonucleotide triphosphate (dNTPs) mix (Bioron GmbH, Germany) and 0.5 U of GoTAq 
DNA polymerase (Promega, WI, USA) and DNase/RNase distilled water (GIBCO, Invitrogen, 
Carlsbad, CA, USA) to fulfil the total reaction volume of 25µl. The sequences of the primer pair 
for ND1 and tRNA Leu (UUR) amplification, designed according to the Cambridge Reference 
Sequence, were: forward (5’-ACACCCACCCAAGAACAGGGTTT-3’) and reverse (5’-
GTAGAATGATGGCTAGGGTACT-3’). PCR reactions were performed in BIO RAD MyCycelTM 
termal cycle (BIO RAD, CA, USA). PCR conditions were: 1 cycle of 5 minutes at 94ºC for initial 
denaturation, followed by 35 cycles of 30 seconds at 94ºC for denaturation, 30 seconds at  58 
ºC  for the appropriated annealing and extension of 30 seconds at 72ºC; the final extension 
was performed in 1 cycle of 5 minutes at 72ºC.  
All primer pairs used for Real-Time PCR with the exception of GNMT which was purchased to 
SABiosciences (Catalog Number PPH12533A) were design based in MAT1A; MAT2A; MAT2B; 
DNMT1 and DNMT3B sequence available on ENSEMBL human database. To rich the optimal 
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conditions, all primer  pairs, were tested using a titration of template and primer, and a “Touch-
down PCR” were performed (1 cycle of 10 minutes at 95ºC for initial denaturation, followed by 
40 cycles of 1 minute at 58ºC - 62ºC for the annealing/extension). In Table 1, the primer 
sequences and the optimal annealing temperatures selected, after PCR optimization are 
describe. 
Table 1. Primers sequences, amplicon sizes and optimal annealing temperature used for real-time PCR 
R-Reverse; F- Forward 
3.4 Agarose gel Electrophoresis 
In order to confirm de right amplification, after de PCR reaction, all products including a 
negative control to check for possible contaminations were separated by electrophoresis on a 
2% w/v agarose (Lonza) gel in 1X SGTB (prepared from stock solution 20x) (Grisp, Porto, 
Portugal). Once polymerized, the gel was place on an electrophoresis apparatus, previously 
filled with running buffer – 1X SGTB. The samples were mixed with Gel Red (Biotium Inc,) plus 
loading buffer.  One kb Plus DNA Ladder (Invitrogen, UK), was used as control for the fragment 
length that is being analysed.  
The fluorescent of the separated PCR products was visualized and photographed in the 
Quantity One – version 4.6.9 in the ChemiDocTM XRS Imaging system (BIO RAD, CA, USA). 
 
Gene Primer sequence Amplicon size (bp) 
Annealing 
Temperature (ºC) 
 
MAT1A 
F: 5’-CAGCAATCCCCAGATATTGCCC-3’ 
108 60 
R: 5’-CTCTGTCTCGTCGGTAGCATAG-3’ 
 
MAT2A 
F: 5’-TGGCAGAACTACGCCGTAATGG-3’ 
103 60 
R:5’-ATGGGAAGCACAGCACCTCGAT-3’ 
MAT2B 
F: 5’-GGCTGTCCTGGAGAACAATCTAG-3’ 
93 60 
R:5’-ACAGTCACAGCACTTTCTTCGAGC-3’ 
DNMT1 
F: 5’-CCAGGCAAACCACCATCACATCT-3’ 
77 60 
R: 5’-GGCTCTTTCAGACTCTTCCTGAG-3’ 
DNMT3B 
F: 5’-CAATCCTGGAGGCTATCCGCA-3’ 
88 60 
R: 5’-CTTAGCAGACTGGACACCTCC-3’ 
HPRT 
F: 5’- GCAGACTTTGCTTTCCTTGGTCAG-3’ 
103 60 
R: 5’- GTCTGGTTATATCCAACACTTCGTG-3’ 
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3.5 Mitochondrial DNA (mtDNA) characterisation and haplogroup affiliation 
3.5.1 MtDNA Sequencing  
PCR products were subjected to a purifying treatment using 1U/µl exonuclease I and 0.05U/µl 
shrimp alkaline phosphatase (both from Fermantas Lisbon, Portugal) at 37ºC for 20 minutes, 
followed by heat inactivation for 15 minutes at 80ºC. For sequencing reaction of the PCR 
products, a mix reaction of 0.5µ of BigDye® Terminator (Perking-Elmer, California, USA), 3.4µl 
of sequencing buffer (Perking-Elmer, California, USA), 0.3µl of primer (forward for ND1 analysis 
and reverse for tRNA Leu(UUR) analysis), 2 µl of purified PCR product and DNase/RNase-free 
distilled water (GIBCO, Invitrogen, Carlsbad, CA, USA) were added to a final volume of 10µl 
were placed in a PCR reaction tube. The sequencing reaction was performed in a BIO RAD 
MyCyclerTM thermal cycle (BIO RAD, CA, USA) with the following conditions: an initial 
denaturation step at 94ºC for 10 seconds, followed by 35 cycles of 10 seconds at 94ºC, 30 
seconds at 56 ºC for the appropriated annealing and elongation of 2 minutes at 60ºC; the final 
elongation was performed in 1 cycle of 10 minutes at 60ºC.  
In order to submit each sample to the ABI prism 3130XL Automatic sequencer Perkin-Elmer, 
Foster City, California, USA), the reaction product had to be purified and precipitated. The 
columns of Sephadex (SephadexTM G-50 Fine, GE Healthcare Bioscience AB, Uppsala, 
Sweden) were prepared adding 750 µl of Sephadex (6.66g/100ml) to each eppendorf and 
further centrifuged at 3200 rpm for 4 minutes at 4ºC. The columns were transferred from the 
collecting tubes to a clean and previously identified tube, and the 10 µl of sequencing product 
was added to the centre of the column. A centrifugation was performed at 3200 rpm, for 4 
minutes at 4ºC. At the final, 15µl of formamide (Applied Biosystem, Norwalk, USA) was added 
to each pellet in order to maintain the single stranded DNA. All the samples were then submitted 
to the ABI prism 3130XL Automatic sequencer (Perkin.Elmer, Foster City, California, USA), for 
further automated sequencing analysis. 
3.5.2 Complete mtDNA sequencing and mtDNA haplogroup affiliation 
The complete mtDNA of the cell lines, 143B, CMPBR3, 3243Cy 9.7, and 3571Cy 1, was 
amplified in 32 overlapping fragment with primers and PCR conditions described in Table 2. 
The same primers were used to directly sequence both strands of the fragments using the 
Promegafmol® DNA Cycle sequencing System and the Usb Thermo Sequence Radiolabelled 
Terminator Cycle Sequencing Kits.  
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Sequences were aligned and compared with the revised Cambridge Reference Sequence 
(rCRS; Andrews et al., 1999), by using the software BioEdit (Hall, 1999). The diversity observed 
in each cell line was automatically classified by using the software mtDNA-GeneSyn (Pereira 
et al., 2009). Haplotypes were also assigned to haplogroups by using the software Haplogrep 
(Kloss-Brandstatter et al., 2011), which also indicates the polymorphisms that are potentially 
private and the ones shared by ancestry. 
Table 2. Primers used in the amplifications and sequencing of mtDNA genome 
Name CRS reference Sequence (5’- 3’) Fragment size (bp) Annealing (ºC) 
L16340 (16318–16340) AGCCATTTACCGTACATAGCACA 681 52 H408 (429–408) TGTTAAAAGTGCATACCGCCA 
L382 (362–382) CAAAGAACCCTAACACCAGCC 603 56 H945 (964–945) GGGAGGGGGTGATCTAAAAC 
L923 (902–923) GTCACACGATTAACCCAAGTCA 607 56 H1487 (1508–1487) GTATACTTGAGGAGGGTGACGG 
L1466 (1445–1466) GAGTGCTTAGTTGAACAGGGCC 629 58 H2053 (2073–2053) TTAGAGGGTTCTGTGGGCAAA 
L2025 (2004–2025) GCCTGGTGATAGCTGGTTGTCC 609 52 H2591 (2612–2591) GGAACAAGTGATTATGCTACCT 
L2559 (2538–2559) CACCGCCTGCCCAGTGACACAT 591 56 H3108 (3128–3108) TCGTACAGGGAGGAATTTGAA 
L3073 (3051–3073) AAAGTCCTACGTGATCTGAGTTC 640 52 H3670 (3690–3670) GGCGTAGTTTGAGTTTGATGC 
L3644 (3625–3644) GCCACCTCTAGCCTAGCCGT 623 58 H4227 (4247–4227) ATGCTGGAGATTGTAATGGGT 
L4210 (4189–4210) CCACTCACCCTAGCATTACTTA 625 55 H4792 (4813–4792) ACTCAGAAGTGAAAGGGGGCTA 
L4750 (4729–4750) CCAATACTACCAATCAATACTC 599 52 H5306 (5327–5306) GGTGATGGTGGCTATGATGGTG 
L5278 (5259–5278) TGGGCCATTATCGAAGAATT 593 58 H5832 (5851–5832 ) GACAGGGGTTAGGCCTCTTT 
L5781 (5762–5781) AGCCCCGGCAGGTTTGAAGC 626 58 H6367 (6387–6367) TGGCCCCTAAGATAGAGGAGA 
L6337 (6318–6337) CCTGGAGCCTCCGTAGACCT 601 58 H6989 (6918–6899) GCACTGCAGCAGATCATTTC 
L6869 (6850–6869) CCGGCGTCAAAGTATTTAGC 578 58 H7406 (7427–7406) GGGTTCTTCGAATGTGTGGTAG 
L7379 (7358–7379) AGAAGAACCCTCCATAAACCTG 580 56 H7918 (7937–7918) AGATTAGTCCGCCGTAGTCG 
L7882 (7861–7882) TCCCTCCCTTACCATCAAATCA 
506 56 H8345 (8366–8345) TTTCACTGTAAAGAGGTGTTGG 
L8299 (8280–8299) ACCCCCTCTAGAGCCCACTG 603 56 H8861 (8882–8861) GAGCGAAAGCCTATAATCACTG 
L8799 (8779–8799) CTCGGACTCCTGCCTCACTCA 638 58 H9397 (9416–9397) GTGGCCTTGGTATGTGCTTT 
L9362 (9342–9362) GGCCTACTAACCAACACACTA 609 56 H9928 (9950–9928) AACCACATCTACAAAATGCCAGT 
L9886 (9865–9886) TCCGCCAACTAATATTTCACTT 617 56 H10462 (10481–10462) AATGAGGGGCATTTGGTAAA 
L10403 10383–10403) (AAAGGATTAGACTGAACCGAA 612 56 H10975 (10994–10975) CCATGATTGTGAGGGGTAGG 
L10949 (10930–10949) CTCCGACCCCCTAACAACCC 617 58 H11527 (11546–11527 CAAGGAAGGGGTAGGCTATG 
L11486 (11467–11486 AAAACTAGGCGGCTATGGTA 629 56 H12076 (12095–12076 GGAGAATGGGGGATAGGTGT 
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L12028 (12008–12028 GGCTCACTCACCCACCACATT 615 58 H12603 (12623–12603 ACGAACAATGCTACAGGGATG 
L12572 (12553–12572 ACAACCCAGCTCTCCCTAAG 591 56 H13124 (13143–13124 ATTTTCTGCTAGGGGGTGGA 
L13088 (13068–13088 AGCCCTACTCCACTCAAGCAC 618 58 H13666 (13685–13666 AGGGTGGGGTTATTTTCGTT 
L13612 (13593–13612 AAGCGCCTATAGCACTCGAA 614 56 H14186 (14206–14186 TGGTTGAACATTGTTTGTTGG 
L14125 (14104–14125 TCTTTCTTCTTCCCACTCATCC 602 58 H14685 (14705–14685 CATTGGTCGTGGTTGTAGTCC 
L14650 (14629–14650 CCCCATTACTAAACCCACACTC 604 58 H15211 (15232–15211 TTGAACTAGGTCTGTCCCAATG 
L15162 (15143–15162 CTCCCGTGAGGCCAAATATC 597 58 H15720 (15739–15720 GTCTGCGGCTAGGAGTCAAT 
L15676 (15657–15676 TCCCCATCCTCCATATATCC 524 56 H16157 (16180–16157 TGATGTGGATTGGGTTTTTATGTA 
L15996 (15975–15996 CTCCACCATTAGCACCCAAAGC 446 58 H16401 (16420–16401 TGATTTCACGGAGGATGGTG 
3.6 Total cell lysates  
Cells lines were seed until reach 70-80% confluence. Cells were washed three times in PBS 
1X and subsequently using RIPA buffer (50mM Tris-HCl, 1% NP-40, 150mM NaCl and 2mM 
EDTA, pH 7,5), containing phosphatase (Sigma-Aldrich, Saint Louis, Missouri, USA) and 
protease (Roche Applied Science) inhibitors, incubated on ice for 15 minutes. The cells were 
scraped off the plates, transferred to micro centrifuge tubes and centrifuged at 14000 rpm for 
15 minutes at 4ºC, the supernatant was collected and the lysates were stored at -20ºC. 
3.7 Western Blot analysis 
Total cell lysates were quantified using a DCTM Protein Assay (BIO-RAD Laboratories, Inc.) 
(BSA standards: 250, 500, 750, 1000, 1500 and 3000µg/mL). (BSA (AppliChem, Darmstadt, 
Germany). The absorbance was read in at 655 nm in microplate reader (BIO RAD, CA, USA). 
Standard curves were accepted for an r2 >0.97. Protein from the cell extracts, were denatured 
with 4X loading buffer (5 minutes at 95ºC), resolved by sodium dodecyl sulphate (SDS)-PAGE 
in a gel 40% bisacrylamide 29:1 (BIO RAD, CA,USA) concentration of 16-10% (v/v) at 100V for 
2.5- 3 hours. Loaded volumes of each input were determined, so the applied protein mass was 
the same for each lane (40 µg). Proteins were, then, electrotransferred onto a Hybond ECL 
nitrocellulose membrane (GE, Healthcare, UK) for 2 hours at 365 mA or 120Volts.  
After staining the membrane with Ponceau S dye (Sigma-Aldrich) to check the uniformity and 
overall effectiveness of protein transfer from the gel to the membrane, membranes were 
blocked for 45 minutes at room temperature (RT) in PBS1X containing 0.1% (v/v) Tween-20 
(Sigma-Aldrich, Saint Louis, Missouri, USA), PBS-T, and 5% (w/v) low-fat dry milk or BSA 
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depending the dilution agent for the primary antibody with gently agitation. The incubation with 
the primary antibodies, diluted in PBS-T containing 5% (w/v) low fat milk or BSA, was carried 
out according to the manufacturer’s instructions (see Table 3) with gently agitation.  Membranes 
were then washed with PBS-T 0.1% and subsequent incubation with suitable horseradish 
peroxidase conjugated secondary antibody diluted 1:2000 in the PBS-T 0.1% containing 5% 
(w/v) low fat milk for 1 hour RT. After the incubation with secondary antibody the membrane 
was washed again and the ECL Plus detection system (Perkin- Elmer, California, USA) was 
added for chemiluminescence detection using Amersham Hyperfilm ECL (GE Healthcare, UK). 
The protein expression levels were quantified using the BIO- RAD quantity One 1-D Analysis 
software (BIO-RAD Laboratories, Inc.) and normalized by the β-Actin or α-tubulin protein levels.  
Table 3. Primary antibodies and respective conditions in the procedure of western blot 
Protein Dilution Incubation 
conditions 
Animal 
origin 
Molecular 
weight (kDa) Commercialized by 
Acetylated-
Lysine 
1:1000 
(BSA 5%) ON at 4ºC Rabbit - 
Cell Signaling 
Technologies, Inc.   
ACL 1:500 (Low fat milk 5%) 1h at RT Rabbit 120 Sigma Aldrich  
SOD-2 1:2500 (Low fat milk 5%) ON at 4ºC Rabbit 24.7 Sigma Aldrich 
SOD-2 k68 1:1000 (Low fat milk 5%) 
ON at 4ºC plus 1h 
at RT Rabbit 25 Abcam
®
 
SIRT3 1:1000 (BSA 5%) ON at 4ºC Rabbit 28 
Cell Signaling 
Technologies, Inc.   
ND1 1:1000 (Low fat milk) ON at 4ºC Mouse 36 
Santa Cruz 
Biotechnology 
NDFUS3 1:500 (Low fat milk) ON at 4ºC Mouse 30 Abcam
®
 
SDHA 1:10000 (Low fat milk) ON at 4ºC Mouse 70 Abcam
®
 
ENOI 1:8000 (Low fat milk) ON at 4ºC Rabbit 47 Abcam® 
eIF4AI 1:1000 (Low fat milk) ON at 4ºC Rabbit 47 Abcam® 
GAPDH 1:8000 (Low fat milk) ON at 4ºC Mouse 36 
Santa Cruz 
Biotechnology 
β-Actin 1:2000 (Low fat milk 5%) 1H; RT Goat 42 
Santa Cruz 
Biotechnology  
α-Tubulin 1:8000  (Low fat milk) 1H; RT Mouse 50 Sigma Aldrich 
ON- Overnight; RT- Room temperature; H- Hour; ACL- ATP citate lyase; SOD-2- Superoxide dismutase Mn; SOD-2K68- 
Superoxide dismutase Mn, acetylated at lysine 68; SIRT3- NAD-dependent protein deacetylase sirtuin-3; ND1- NADH 
dehydrogenase subunit 1; NDFUS3- NADH dehydrogenase (ubiquinone) Fe-S protein 3; SDHA- succinate dehydrogenase 
complex, subunit A; ENOI- α-Enolase; eF4AI- eukaryotic initiation factor 4AI; GAPDH- Glyceraldehyde-3-phosphate 
dehydrogenase. 
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3.8 Reserve Transcriptase – Polymerase Chain Reaction (RT-PCR) 
The cDNA synthesis was performed using 100ng of RNA, 100µM Random hexamer primer 
(Fermentas, Lisbon, Portugal), 220U RevertAidTM Reverse Transcriptase, 5X reaction buffer, 
20U RiboLockTM RNase Inhibitor (all from Fermentas, Lisbon, Portugal) and 40mM dNTPs mix 
(Bioron GmbH, Germany) to a final volume of 20µl. The thermal cycling conditions were 10 
minutes at 25ºC followed by 60 minutes at 42ºC and finally 10 minutes at 70ºC. The reaction 
was performed on Bio-Rad MyCycleTM Thermal Cycle (BIO RAD, CA, USA). A negative control 
was included to check possible RT-PCR contamination. 
3.9 Real time PCR/ qPCR 
Real-time PCR was performed to quantify GNMT; MAT1A; MAT2A; MAT2B; DNMT1; DNMT3B 
mRNA levels in the different cells lines. The reaction was performed according to 
manufacturer’s instructions using the RT2 Real-TimeTM SYBR Green/ROX PCR master mix 
(Qiagen, Hilden, Germany) which contains a high-performance HotStart DNA Taq polymerase, 
nucleotides and ROX. The housekeeping gene used as control was HPRT (primers already 
available in our lab). Each sample was efficiently corrected against a standard curve for each 
target. Afterwards, samples were normalized to an endogenous control (HPRT) to ensure that 
expression levels were correctly compared among each other. Those two parameters ensure 
that samples are standardized compared and correctly analysed. 
3.10 Complex I Enzyme Activity 
The activity of the mitochondrial complex I (NADH:ubiquinone oxidoreductase) was evaluated 
enzymatically by using the Complex I Enzyme Activity Microplate Assay Kit (ab109721) 
(Abcam®), according to the manufacturer’s instructions. Briefly, mitochondrial activity is 
determined by following the oxidation of nicotinamide adenine dinucleotide (NADH) to NAD+ 
and the simultaneous reduction of a dye leading to increased absorbance at 450 nm. The 
complex I activity is expressed as milli-units of optical density (mOD) (Figure 8).  
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Figure 8. Complex I Enzyme Activity Microplate Assay Kit (ab109721) (Abcam®); Substrate was NADH and the product was 
NAD+ . 
The cells were seeded until reach 70-80% confluence, washed in PBS 1X, trypsinized (0.05% 
trypsin-EDTA) and pelleted (1200rpm, 5 minutes). After, 350-500 µl of PBS 1X (depending of 
the pellet) was added to each pellet, and 1/10 of the volume of a detergent was added and 
incubated on ice for 30 minutes to perform protein extraction. After, the samples were 
centrifuged at 12,000 x g for 20 minutes and the supernatant collected. The protein samples 
were quantified using DCTM Protein Assay based on the well documented Lowery assay (BIO-
RAD Laboratories, Inc.) and 200µg of protein sample was added in each well, including a 
control buffer as null reference and incubated for 3 hours at RT. After the incubation the wells 
were washed three times with buffer and 200µl of assay solution (containing buffer, NADH 
40mM and Dye) was added to each well. The absorbance was measure at 450 nm at 
approximately 30 second’s intervals for 30 minutes and auto shake between readings. 
3.11 Luminescent ATP Detection Assay  
The global cellular adenosine 5’-triphosphate (ATP) levels were quantified using Luminescent 
ATP Detection Assay Kit (ab113849, Abcam®) according to the manufacturer’s instructions. 
These ATP assay is based on the production of light caused by the reaction of ATP with added 
luciferase and D-luciferin; the emitted light is proportional to the ATP concentration inside the 
cell and is expressed in Luminescent count/cell. The luminescence was measure in the 
SynergyTM 4 Multi-Mode Microplate Reader – (BioTeck® - Instruments Inc. Vermont USA). The 
reaction can be summarized as follows: 
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Briefly, 15000 cells/well were seeded into a 96-well plate, in 100µl of complete culture medium, 
24 hours before the ATP assay. After the 24 hours, 100μL of complete culture medium was 
added into the empty wells of the plate allocated for the standard dilutions of ATP and the 
negative control; 50µl of detergent was added to each well and incubated for 5 minutes in an 
orbital shaker at 700rpm. To perform the standard curve, 10µl of ATP standard was added in 
a 1:4 dilution series from 10μM to 610pM final concentration and incubated for 5 minutes in an 
orbital shaker at 700 rpm. In order to measure the luminescence 50μL of the reconstituted 
substrate solution was added to each well and shake the microplate for five minutes in an orbital 
shaker at 700rpm and incubated for 10 minutes in the dark the microplate. The luminescence 
was measure in the SynergyTM 4 Multi-Mode Microplate Reader – (BioTeck® - Instruments Inc. 
Vermont USA). 
3.12 Quantification of global DNA methylation  
The global DNA methylation level was determined using the EpiSeeker methylation DNA 
quantification Kit (Fluorometric) (ab117129 Abcam®). In this assay, DNA was bound to strip 
wells that were specifically treated to have a high DNA affinity. The methylated fraction of DNA 
was detected using capture and detection antibody and then quantified fluorometrically by 
reading the relative fluorescence units (RFU). The amount of methylated DNA is proportional 
to the fluorescence intensity measured.  
To perform this evaluation, DNA was extracted from cell lines and quantified using NanoDrop 
ND-1000 Spectrophometer (Nanodrop Technologies, Inc., Delaware, USA). DNA 
concentration was adjusted to 100ng/µl.  The DNA samples (100ng) and the diluted standards 
(0.5-10.0ng/µl) was further added to 80µl of binding solution for each well and incubated for 90 
minutes at 37ºC. The wells were washed three times, followed by incubation with the capture 
antibody for methylated DNA (1:1000) and incubated at RT for 60 minutes. After the incubation 
time the wells were washed three times, and the detection antibody (1:2000) was added and 
incubated at RT for 30 minutes. Each well were washed four times followed by the addition of 
the enhancer solution (1:5000) and incubated for 30 minutes at RT. The enhancer solution was 
removed from each well and each well was washed five times followed by the addition of the 
Fluoro-development solution to each well, and incubated for 4 minutes in dark. The RFU was 
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measure using the SynergyTM 4 Multi-Mode Microplate Reader – (BioTeck® - Instruments Inc. 
Vermont USA) at Ex/Em= 530/590 nm.  
3.13 Genomic 5-hydroxymethylcytosine levels evaluation  
The global levels of 5-hydroxymethylcytosine (5-hmC) was evaluated using the GpGenomeTM 
5-hmC quantification kit (EMD Millipore Corporation, Billerica, MA, USA) which provides a rapid, 
efficient automation-compatible ELISA-based protocol for sensitive quantification of 5-hmC in 
a wide range of DNA. 
This assay is designed to determine the levels of 5-hmC DNA in a sample relative to a standard 
curve. This solid-phase assay is possible because antibodies can be attached to plastic (see 
Figure 9), requires two antibodies that bind to epitopes that do not overlap on the antigen. 
 
Figure 9.  Illustration of CpGenome 5-hmC quantitation kit assay principle. 
To perform this evaluation, DNA was extracted from cell lines with different passages and 
quantified using NanoDrop ND-1000 Spectrophometer (Nanodrop Technologies, Inc., 
Delaware, USA). The DNA concentration was adjusted to 100ng/µl. 
In order to bind the 5-hmC antibody to the surface of the well, the antibody was prepared in the 
assay buffer to the final concentration of 1ng/µl and 100µl of the 1ng/µl 5-hmC antibody solution 
was added to each well and incubated at 37ºC for 1 hour. After the incubation time the wells 
were washed three times with the assay solution.  
DNA samples were placed in a thermo cycle and incubated at 98ºC for 5 minutes to denature 
the DNA and after 5 minutes the samples were immediately placed on ice for 10 minutes to 
ensure that DNA remain in a single strand. The single strand DNA samples and 5-hmC 
standards were prepared to a final concentration of 1ng/µl, and 100µl of the diluted samples 
and 5-hmC standards were added to each well and incubate at 37ºC for 1 hour. After the 
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incubation time the wells were washed three times and 100µl of diluted HRP detection antibody 
(1:100) were added to each well and incubated for 30 minutes at 37ºC. 
For colorimetric detection, the wells were washed three times with assay buffer and 100µl of 
HRP detection reagent was added. The absorbance in each well was measure at 405 nm using 
the SynergyTM 4 Multi-Mode Microplate Reader – (BioTeck® - Instruments Inc. Vermont USA). 
3.14 Immunoprecipitation protocol  
3.14.1 Preparing Cell Lysates   
The cells were plated until reach 70-80% of confluence. The culture medium was aspirated and  
the cells were washed three times with PBS1X, and 350µl of 1X Cell Lysis Buffer (20Mm Tris 
(pH7.5), 150 nM EDTA, 1% Triton x-100, 2.5mM Sodium pyrophosphate, 1 mM β-
glycerophosphate, 1mM Na3VO4,1µg/ml leupetin) (Cell Signaling Techonology ®) was added to 
each plate (75 cm2) and incubated on ice for 10 minutes. The cells were scraped off the plates 
and transferred to microcentrifuge tube followed by centrifugation for 10 minutes at 14,000 x g, 
4ºC. The supernatant was transferred to a new tube and the lysates were stored at -20ºC. 
3.14.2 Immunoprecipitation  
Total cell lysates were quantified using a DCTM Protein Assay (BIO-RAD Laboratories, Inc.). In 
order to perform a cell lysate pre-clearing 750µg of protein was added to 35 µl of Protein A 
agarose beads (50% bead slurry) (Cell Signaling Techonology ®) and incubate at 4ºC for 1 
hour. After, the protein samples were centrifuged at 4ºC for 10 minutes and the supernatant 
was collected into a new microcentrifuge tube.   
To perform a pull down of the acetylated lysines proteins the antibody against acetylated lysine 
(1:100) (polyclonal rabbit) (Cell Signaling Technologies, Inc.) was added to each sample, the 
same concentration of antibody was added in the negative control. As a negative control an 
antibody against TOM-20 (polyclonal rabbit) (Santa Cruz Biotechnology, Inc.) was used. The 
samples and the negative control, after the addition of the respective antibody, were incubated 
with gentle rocking overnight at 4ºC. After the incubation time, 35µl of Protein A beads (50 % 
beads slurry) was added and the samples incubated with gently rocking for 2 hours at 4ºC 
followed by a microcentrifuge for 30 seconds at 4ºC. The pellet was washed four times with 
500µl of 1X cell lysis buffer. 
The pellet was resuspended with 30µl of 3x SDS sample buffer followed by heating at 95ºC for 
5 minutes and centrifuged for 1 minute at 14,000 x g. The samples, controls and total cell 
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lysates of each cell line were load on SDS-PAGE gel 40% bisacrylamide 29:1 (BIO-RAD 
Laboratories, Inc.) concentration of 12% (v/v). 
3.15 Two-dimensional (2-D) gel electrophoresis  
3.15.1 Protein Precipitation  
To perform the 2-D gels, the protein samples were quantified using a DCTM Protein Assay (BIO-
RAD Laboratories, Inc.). For the 7cm strip and the 11cm strip, 150 µg and 300 µg of protein, 
respectively, was used. 
Protein precipitation was performed using the ProteoExtract® Protein precipitation Kit 
(Calbiochem®). Protein samples analysis is often hampered by the presence of non-protein 
impurities such as buffer, salts and detergents that interfere with electrophoretic separations or 
enzymatic digestion. The ProteoExtract® Protein precipitation Kit (Calbiochem®) provides a fast 
and efficient method for concentrating and cleaning up proteins.  
After the quantification of the protein samples the volume was adjusted to 200µl with RIPA 
buffer, and 800µl of cold precipitation agent (-20ºC) was added to each sample. The samples 
were incubated for 1 hour at -20ºC followed by centrifugation at RT at 10,000 x g to pellet the 
proteins. The supernatant was carefully aspirated without disturbing the pellet. The pellet was 
washed twice by adding 500µl of cold wash solution (-20ºC) and vortex briefly followed by 
centrifugation for 2 minutes at RT at 10,000 x g to pellet the proteins. To dry the pellet, the 
tubes were left open for 45 minutes on the lab bench. 
3.15.2 Rehydration and sample application  
The protein samples was resuspended/rehydrated in 125µl, for 7cm strip, or 200µl, for 11cm 
strip, in IEF buffer [8M urea, 2% CHAPS and 50nM dithiothreitol (DTT)]  to the IEF buffer was 
added Bio-Lyte ampholytes (BIO-RAD Laboratories, Inc.), and the samples were incubated for 
1 hour at RT with gently agitation. After the incubation time the indicated volume of each sample 
(125µl for 7cm strip or 200µl for 11cm strip) was added as a line along the edge of each cannel 
in a clean dry disposable rehydration/equilibration tray. When all protein samples have been 
loaded into the rehydration/equilibration tray, the IPG strips (BIO-RAD Laboratories, Inc.) were 
placed with the gel facing down, onto the sample and incubated for 30 minutes at RT. After the 
30 minutes, each of the IPG strips was overlaid with 2.5ml of mineral oil and the 
rehydration/equilibration tray was cover with the plastic lid and left overnight to rehydrate the 
IPG strips and load the protein samples.  
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Isoelectric focusing was performed in a Preotean IEF cell (BIO-RAD Laboratories, Inc.) under 
the following conditions: (i) 250 V, 15 minutes; (ii) voltage gradient up to 4000 V; and (iii) 4000 
V until reach 14000 V-hour. The temperature was maintained at 20ºC and the current was kept 
at 50 microA per strip. At the end of this step the IPG strips were stored at -20ºC.  
Upon completion, strips were equilibrated in buffer containing 6M urea, 0.375 M Tris-HCl, pH 
8.8, 2% SDS, 20% glycerol and 2% w/v DTT for 10 minutes, followed by a second equilibration 
using the same buffer containing 6M urea, 0.375 M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 
2.5% w/v iodoacetamide instead of DTT for another 10 minutes, this incubation was performed 
in the dark.  
After the incubation time, the IPG strip was placed into a SDS-PAGE gel containing an IPG 
well filled with melted overlay agarose. The electrophoresis was performed at 150-200V for 45 
minutes. When the electrophoresis was concluded, the SDS-PAGE gel was washed with 
distilled water three times for 10 minutes. The protein samples were electrotransferred onto a 
Hybond ECL nitrocellulose (GE, Healthcare, UK) membrane for 2 hours at 365 mA or 120Volts 
followed by blocking the nitrocellulose membrane for 45 minutes in PBS-T 0.1% containing 5% 
(v/w) BSA (Sigma-Aldrich, Saint Louis, Missouri, USA) and the membrane was incubated with 
the antibody against acetylated lysines (1:2500) (Cell Signaling Technologies, Inc.) overnight 
at 4ºC.    
3.15.3 Coloration with Coomassie Blue 
Coomassie dyes are a family of dyes commonly used to stain proteins in sodium dodecyl 
sulphate and blue native polyacrylamide gel electrophoresis. This treatment allows the 
visualization of protein spots. 
After completed electrophoresis, the gel was washed three times with distilled water for 10 
minutes followed by the addiction of Coomassie Blue (Thermo Scientific) and incubated for 12-
14 hours at RT with gently rocking. 
3.16 Mass Spectrometry Methods for Studying differentially acetylated proteins  
Differentially acetylated proteins (based on the differences in the intensity spots), between the 
two cell lines (143B and 143B Rho0), were identified by Mass Spectrometry. For protein 
excision from the gel, was used a gel spot picker (OneTouch 2D gel spot picker, 1.5 mm 
diameter, Gel Company, USA), and the gel spots were transferred into a 0.25 mL 
microcentrifuge tube. 
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To each of the protein gel spots 200µl of a solution containing 50 % methanol in 50mM 
NH4HCO3 (1:1 v/v) was added and mixed for 1min at the top speed of microcentrifuge tube 
mixer. The supernatant was discarded and this step was repeated once. For samples 
dehydration, 200µl of the dehydration solution at 50 % of Acetonitrile (ACN) in 50mM NH4HCO3 
(1:1 v/v) (recently prepared) was added and mixed for 5 min at the maximum speed of the 
microcentrifuge tube mixer and the supernatant was rejected followed by the addition of 200μL 
of ACN and incubate 30s.  
The protein gel spots samples were dried in a vacuum centrifuge concentrator until complete 
drying of the sample. (5–10 min). After, 100µl of the solution of 25mM DTT in 50mM NH4HCO3 
was added to each sample, and incubated for 20 minutes at 56ºC. After the incubation time 
100μL of the alkylation solution freshly prepared 55mM IAA (iodoacetamide) in 50mM 
NH4HCO3 was added, and incubated in the dark for 20 min at room temperature. The 
supernatant was discarded and each sample was washed with 200µl of ultrapure water by 
briefly vortex mixing, this step was preformed twice.  
In order to perform the second dehydration of the samples 200µl of the dehydration solution at 
50 % of ACN in 50mM NH4HCO3 (1:1 v/v) was added and mixed for 5 min at the maximum 
speed of the microcentrifuge tube mixer and the supernatant was rejected followed by the 
addition of 200μL of ACN and incubate 30 s. The protein gel spot samples were dried in a 
vacuum centrifuge concentrator until complete drying of the sample (5–10 min).  
To perform the tryptic digestion each gel sample was rehydrated with 20µl of 2ng/µl trypsin 
(Trypsin Gold, Mass Spectrometry Grade- Promega, WI, USA) in 0.01% surfactant  
(ProteaseMAX™ Surfactant,Trypsin Enhancer Promega, WI, USA), 50mM NH4HCO3 for 10 
minutes. After the 10 minutes, the samples were overlaid with 30µl of 0.01% surfactant in 50mM 
NH4HCO3 and gently mix followed by incubation at 37ºC for 3hours.  The content was pipetted 
and resuspended twice and transferred into a new tube, 20µl of 2.5% trifluoroacetic acid (TFA) 
was added to the gel pieces and mixed in a microcentrifuge tube shaker at the maximum speed 
for 15 minutes. 
The extract and the trypic digest were combined and the gel pieces were discarded. The 
combined solution was centrifuged for 10 minutes at 14.000 rpm and the supernatant was 
transferred into a new tube. In this step, if the trypic digest is not going to be analysed within a 
few hours, the samples can be stored at -20ºC.  
Using Ziptip C18 (EMD Millipore Corporation, Billerica, MA, USA), 10µl of wetting solution 
(100% ACN) was aspirated  and dispensed to wash, this step was performed twice followed by 
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pipetting 10µl of equilibration solution (0.1% TFA in Mili-Q grade water) and dispensed, this 
step was performed twice.  
In order to bind the peptides, the samples was aspirated and dispensed in ten cycles (it is 
important to aspirate the digest into a maximum capacity of the tip) followed by aspiration of 
wash solution (0.1% TFA in Mili-Q grade water) into the tip and dispensed to waste.  
To perform the elution of the peptides with Matrix Assisted Laser Desorption Ionization (MALDI) 
matrix [1.2 µl of elution buffer (0.1% TFA/ 50% ACN) with NALDI matrix was previously 
pipetted], the samples was aspirated with the MADI matrix, and dispense in ten cycles and 
plated into a MALDI sample plate. 
3.17 Statistical Analysis  
Whenever adequate, the results are presented as mean ± standard deviation. Statistical 
analysis was performed using One-Way ANOVA and posterior Bennett and Tukey tests, with 
p< 0.05 as the level of significance, in Graph Pad Prism software version 6. 
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4.1 Cybrid Cell Lines 
In order to evaluate the possible role of mitochondrial dysfunction, caused either by 
mutations/variants in mtDNA or mtDNA depletion, in the epigenetic landscape of the cell, we 
decided to take advantage of a suitable cell model. Thus, we choose a model, already 
established in our lab characterized by a genetic impairment of OXPHOS proteins; it should be 
noted that OXPHOS has both mtDNA and nDNA encoded proteins. To study specifically the 
functional effect of mtDNA mutations/variants, nuclear effects must be excluded and, so, 
cybrids cell lines were used.  
The cybrid cell lines displaying the mtDNA ND1 gene mutation (3571InsC), were already 
available in our lab. These cybrid cell lines were constructed using the cell line 143B Rho0, 
used as recipient cell line, whereas the cell line XTC.UC1 (harbouring the mtDNA ND1 gene 
mutation) was used as donor cell line. Three cybrid cell lines resulted from this construction, 
two of them had different percentage of heteroplasmy, for the mtDNA ND1 gene mutation 
(3571Cy 1 and 3571Cy 22), and one cybrid cell line with wt homoplasmy for the mtDNA ND1 
gene (Cy 24). 
Taking into consideration that our purpose was to inactivate OXPHOS, we decided to take 
advantage of a known pathogenic mitochondrial mutation – an A-to-T transition at mtDNA 
nucleotide position 3243 in the tRNA Leu (UUR) gene – that will presumably affect all complexes 
with mtDNA encoded proteins (I, III, IV and V). This cybrid cell line was already established in 
our lab. To build the A3243T cybrid, platelets were extracted from a patient with mitochondrial 
myopathy due to a germ line A3243T mutation. Platelets were then fused 143B Rho0 cell line. 
This cybrid was called 3243Cy 9.7. 
In addition, to the aforementioned cybrid cell lines used, we had already available a cybrid cell 
line resulting from the fusion of 143B Rho0 cell line and platelets from a healthy individual - 
CMPBR3 cybrid cell line, and the parental cell line of the 143B Rho0 – 143B. These two cell 
lines were used because we wanted to test if the mtDNA belonging to different haplogroups, 
with the same nuclear background (nDNA), have some influence the cellular epigenetic 
landscape.  
Additionally, we also used a cell line without mtDNA (143B Rho0) in order to understand the 
putative role of mtDNA in the regulation of the cellular epigenetic landscape. The 143B Rho0 
cell line has already been used in other studies using cybrid cell lines, with the aim of studying 
the possible effect of mitochondrial dysfunction in various aspects of cellular physiology  (Singh 
et al., 2005). 
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4.2 Evaluation of mtDNA mutation status in the cybrid cells 
4.2.1 Mutations status of the cybrid cell lines (3571Cy 1 and 3571Cy 22) displaying 
a mtDNA ND1 gene mutation – (3571InsC) 
 
  
 
 
Figure 10. Sequence analysis of the mtDNA ND1 gene. A. Electropherogram of 3571Cy 1 showing the level of the C insertion 
at bp3571, according to the Cambridge Reference Sequence and, by an analysis of the electropherogram, presented 
approximately 60% of the mutation. B. An analysis of the electropherogram of 3571 Cy 22, presented approximately 80% of the 
mutation. C. Electropherogram of Cy 24 showing the normal sequence of the mtDNA ND1 gene. 
We confirmed the presence of the mtDNA ND1 gene mutation in the cybrid cell lines, 3571Cy 
1 and 3571Cy 22. An analysis of the electropherograms of the 3571Cy 1 and 3571Cy 22 cybrid 
cell lines, presented approximately 60% and 80% of the mtDNA ND1 gene mutation, 
respectively. (Figure 10 A and B). Furthermore, we also confirmed the absence of mtDNA ND1 
gene mutation in the Cy 24 cell line (Figure 10 C). 
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4.2.2 Mutation status of the cybrid cell line displaying a mtDNA tRNA Leu (UUR) 
gene mutation - A3243T cybrid 
 
Figure 11. Sequence analysis of the mtDNA tRNA Leu (UUR) gene in the cybrid 3243Cy 9.7. Electropherogram showing the level 
of A-to-T transition at mtDNA nucleotide position 3243, according to the Cambridge Reference Sequence (superimposed peaks 
suggest 60% mutated mtDNA). 
We confirmed the presence of the mtDNA tRNA Leu (UUR) gene mutation in the 3243Cy 9.7 cybrid 
cell line. An analysis of the electropherogram suggest the presence of approximately 60% of 
the mtDNA tRNA Leu (UUR) gene mutation, in the 3243Cy 9.7 cybrid cell line (Figure 11).  
4.2.3 Sequencing of the 143B, 143B Rho0 and CMPBR3 cell lines  
In order to be sure the mtDNA mutations under study were specific of the 3571Cy 1, 3571Cy 
22 and 3243Cy 9.7, we confirmed its absence in CMPBR3, 143B and 143B Rho0. As seen in 
Figure 12, no other cell lines than 3571Cy 1 and 3571Cy 22 have the 3571InsC mutation, and 
only the 3243Cy 9.7 presents the A3243T mutation at the mtDNA tRNA Leu (UUR) gene (Figure 
13). It should be stated that we could obtain a PCR product from 143B Rho0; however, after 
sequencing, it displayed numerous point mutations which can be due to fragmentation of 
mtDNA or to amplification of nuclear pseudogenes of mtDNA (Parr et al., 2006). 
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Figure 12. Sequence analysis of the mtDNA ND1 gene. A. Electropherogram of 143B cell line showing the normal sequence of 
the mtDNA ND1 gene. B. An analysis of the electropherogram of CMPBR3 cell line, showing the absence of mutation in mtDNA 
ND1 gene. C. Electropherogram of 143B Rho0 cell line, showing mutations all over the sequence.  
 
Figure 13. Sequence analysis of the mtDNA tRNA Leu (UUR) gene. A. Electropherogram of 143B cell line, showing the absence 
of the A-to-T transition at mtDNA nucleotide position 3243. B. Electropherogram of CMPBR3 cell line, showing the absence of 
mutation in mtDNA tRNA Leu (UUR)  gene at mtDNA nucleotide position 3243. C. Electropherogram of 143B Rho0 cell line, showing 
mutations all over the sequence. The arrow points the theoretical substitution place. 
To ensure the absence of mtDNA in 143B Rho0 cells, the expression of mtDNA-encoded 
cytochrome oxidase subunit II (COX II) protein was assessed. Figure 14 shows that 143B Rho0 
cell line does not express this enzyme, comparing with all other cell line used, confirming the 
mtDNA depletion in 143B Rho0 whereas cybrids cell lines showed expression of this enzyme.  
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Figure 14. Analysis of protein levels of COXII in all cell lines. COX II indicates cytochrome oxidase subunit II. 
4.2.4 Mitochondrial DNA (mtDNA) haplogroup affiliation of the 143B, CMPBR3, 
3243Cy 9.7 and 3571Cy 1 cell lines  
For the mtDNA haplogroup affiliation of the 143B, CMPBR3, 3243Cy 9.7 and 3571Cy 1 cell 
lines, the complete mtDNA sequencing was performed. The data was analysed using the 
Haplogrep software (http://haplogrep.uibk.ac.at/) that is associated with the Phylotree data 
base (http://www.phylotree.org/). 
After the analysis of the sequence data the haplogroups of each cell line were determined. The 
mtDNA of the 143B cell line haplotype can be affiliated to the haplogroup X2e1, the mtDNA of 
the CMPBR3 cell line to the haplogroup J1ba1, the mtDNA of the 3243Cy 9.7 cell line to the 
haplogroup H1aW and the mtDNA of the 3571Cy 1 cell line to the haplogroup H1b1+16362.  
The mtDNA of the 143B, CMPBR3 and the 3243Cy 9.7 cell lines belongs to different 
haplogroups, and on the other hand, the mtDNA of the cybrids 3571Cy 1 and 3243Cy 9.7 
belongs to the same haplogroup, although exhibiting differences regarding the subgroup 
(Figure 15).  
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Figure 15. Mitochondrial DNA (mtDNA) haplogroup affiliation. A. Haplogroup affiliation of the mtDNA of the 143B cell line. B. 
Haplogroup affiliation of the mtDNA of the CMPBR3 cell line. C. Haplogroup affiliation of the mtDNA of the 3243Cy 9.7 cell line. D. 
Haplogroup affiliation of the mtDNA of the 3571Cy 1cell line. 
4.3 Complex I activity 
To test the effect of mtDNA mutations/variants (143B, CMPBR3, 3243Cy 9.7, 3571Cy 1 3571Cy 
22 and Cy 24) as well as the absence of mtDNA (143B Rho0) in mitochondrial function, the 
activity of mitochondrial complex I in these cell lines was accessed.  
Comparing with the parental cell line (143B), a statistically significant increase in complex I 
activity was observed in Cy 24 cybrid cell line (Figure 16 A).  
Differences in Complex I activity were also observed between cell lines with mtDNA belonging 
to different haplogroups (Figure 16 B). The haplogroup H (Cy 24 cell line) showed the highest 
complex I activity, being statistically significant higher (p<0.05) than that of haplogroup X (143B 
cell line). Additionally, we also observed an increase in complex I activity in the haplogroup J 
(CMPBR3 cell line) compared with the haplogroup X (143B cell line), although this increase 
was not statistically significant. The 143B Rho0 cell line (with no mtDNA) showed the lowest 
complex I activity, comparing with all cell lines [Cy 24 cell line (haplogroup H) (p<0.01), 
CMPBR3 cell line (haplogroup J) (p<0.05)] (Figure 16 B). 
Concerning the cell lines with mtDNA belonging to the same haplogroup (Cy 24, 3571Cy 1, 
3571 Cy22 and 3243 Cy9.7) (Figure 16 C), all cybrid cell lines harbouring mtDNA mutations 
revealed a statistically significant decrease in complex I activity when compared and 
normalized to the Cy 24 (wt mtDNA) cell line [Cy 24 vs 3571Cy 1 (p<0.01); Cy 24 vs 3571 Cy 
22 (p<0.05) and  Cy 24 vs 3243Cy 9.7 cell line (p<0.05)] (Figure 16 C). 
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Figure 16. Analysis of complex I activity. A. Overview of complex I activity in all cell lines compared with the 143B cell line. B. 
Analysis of complex I activity in cell lines harbouring mtDNA belonging to different haplogroups (143B- haplogroup X; CMPBR3- 
haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of complex I activity in cell lines 
belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 22 and 3243Cy 9.7), normalized 
to Cy 24 cell line. The activity of Complex I is proportional to the increase in absorbance at 450 nm. Activity mOD indicates that 
activity was measure at 450 nm; RQ - relative quantification. Data correspond to two biological replicas done in duplicates. Bars, 
standard deviation; columns, mean. The asterisks indicates the level of statistical significance (*p<0.05; ** p<0.01). Data were 
subjected to one-way ANOVA and a posterior Bennett and Tukey test.  
4.4 Analysis of ND1 protein expression level in cybrids with mtDNA ND1 gene mutation 
The mtDNA ND1 gene mutation (3571InC) present in 3571Cy 1 and 3571Cy22 cybrid cell lines 
give rise to a ND1 truncated protein (Bonora et al., 2006), and the percentage of heteroplasmy 
in the two cell lines is different. For that reason, we performed a western blot analysis for ND1 
protein expression level in these cybrids, in cybrid Cy 24 that was used as control, as well as 
in the parental cell line (143B). This experiment was done only once, making, the statistical 
analysis not feasible. 
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The two cybrid cell lines (3571Cy 1 and 3571Cy 22) harbouring mtDNA ND1 gene mutation 
had a decreased  ND1 protein expression level, comparing with the Cy 24 cell line. 
Additional, the 143B cell line presented a decrease in the ND1 protein levels compared with 
the Cy 24 cell line (Figure 17 A and B). Concerning NDUFS3 protein expression level, a nDNA 
encoded mitochondrial protein used as a control, no differences between the cell lines analysed 
were observed, either if the protein levels (NDUFS3) were normalized for β-actin (cytoplasmic 
protein) or SDHA (mitochondrial protein ) (Figure 17 C and D).  
 
Figure 17. Western blot analysis for ND1 and NDUFS3 protein levels. A. western blot analysis for ND1 and NDUFS3 proteins, 
and β-Actin protein as an endogenous control and SDHA protein as a control of mitochondrial loading. One immunoblot of two 
experiments is shown. B. Quantification of ND1 protein levels normalized to SDHA protein expression levels. C. Quantification of 
NDUFS3 protein levels normalized to SDHA protein expression level; D. Quantification of NDUFS3 protein levels normalized to β-
Actin protein expression level. 
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4.5 Analysis of global ATP levels  
After the analysis of complex I activity, and once we have seen differences in its activity in 
some of the cell lines analysed, we assessed the global production of ATP level in different cell 
lines in study, aiming to verify if the differences in mitochondrial complex I activity is reflected 
in the global levels of ATP production.  
No statistically significant differences, in the global ATP levels, were observed between the cell 
lines (CMPBR3, 3243Cy 9.7, 3571Cy 1, 3571Cy 22, Cy 24 and 143B Rho0) compared with the 
parental cell line (143B) (Figure 18 A).  
No statistically significant differences, in global ATP levels, were also observed in the cell lines 
with mtDNA belonging to different haplogroups (Figure 18 B), however the haplogroup J 
(CMPBR3) together with the 143B Rho0 (without mtDNA) cell lines showed a lower global ATP 
level, compared to cell lines with mtDNA belonging to haplogroup X (143B) and haplogroup H 
(Cy 24) (Figure 18 B). The data were normalized to 143B cell line. 
In the cell lines with mtDNA belonging to the same haplogroup (Cy 24, 3571Cy 1, 3571 Cy 22 
and 3243Cy 9.7), no statistically significant differences were observed (Figure 18 C), however 
the 3243Cy 9.7 cybrid cell line presented the lowest global ATP level (Figure 18 D). The data 
were normalized to Cy 24 cell line.  
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Figure 18. Analysis of global ATP levels. A. Overview of the global ATP levels in all cell lines compared with 143B cell line. B. 
Analysis of the global ATP levels in cell lines harbouring mtDNA belonging to different haplogroups (143B- haplogroup X; CMPBR3- 
haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to143B cell line. C. Analysis of the global ATP levels in cell lines 
belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 22 and 3243Cy 9.7), normalized 
to Cy 24 cell line. RQ indicates relative quantification. Data correspond to three biological experiments done in triplicates. Bars, 
standard deviation; columns, mean. Data were subjected to one-way ANOVA and a posterior Bennett and Tukey test. 
4.6 Global metabolic profile of the cell lines 
The global metabolic profile was achieved from an engaged service to the Metabolon® 
Company. 
Changes in metabolic pathways, namely changes in the metabolite levels, were observed in 
mtDNA cells depleted (143B Rho0) or bearing mutations/variants in mtDNA (143B, CMPBR3 
3243Cy 9.7 and 3571Cy 1) (see Table 4). The depletion of mtDNA leads to a blockage of TCA 
cycle that can be seen by the alterations in the metabolite levels of this pathway. Furthermore, 
all cell lines presented alterations in the levels of some of the metabolites involved in PTMs and 
epigenetic landscape modifications, namely in the acetylation (acetyl-CoA) and methylation 
(methionine and s-adenosylhomocysteine) compared with the parental cell line (143B).  
The 143B Rho0, CMPBR3 and 3243Cy 9.7 cell lines showed alterations in the metabolite levels 
involved in the methylation reactions. These cell lines presented a statistically significant 
increase (p<0.05) in the levels of methionine and cysteine compared with the parental cell line 
(143B) (Table 4).  
Concerning the coenzyme A metabolism the 143B Rho0 cell line showed a statistically 
significant increase (p<0.05) in the metabolites evaluated for this pathway, specifically the 
coenzyme A and acetyl-CoA compared with the 143B cell line. Additionally the cell lines bearing 
mtDNA mutations (3571Cy 1 and 3243Cy 9.7) also presented an increase levels in these 
metabolites compared with the parental cell line (143B). 
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Regarding the redox states, all cell lines evaluated showed an increase in the metabolites 
involved in the glutathione pathway, such as glutathione reductase (GSH), glutathione oxidase 
(GSSG) and cysteine-glutathione disulfide, compared with the 143B cell line (Table 4).  
This data, together with data on mitochondrial complex I activity, suggest that mtDNA 
mutations/variants induces changes in global cell metabolism. 
Table 4. Metabolite levels in the cell lines compared with 143B cell line. 
 
Red and green shaded cells indicate p≤0.05 (red indicates that the mean values are significantly higher for that comparison; green 
values significantly lower). Light red and light green shaded cells indicate 0.05<p<0.10 (light red indicates that the mean values 
trend higher for that comparison; light green values trend lower). All data are normalized to Bradford protein assay values. 
4.7 Analysis of DNA methylation status   
4.7.1 Evaluation of 5-methylcytosine   
The global levels of 5-methylcytosine (5-mC) of all cell lines were evaluated using an easy and 
fast approach, a kit that allows the calculation of the percentage of global DNA methylation (5-
mC) in DNA isolated from all cell lines. 
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According to the results, either the presence of mtDNA mutations/variants as well as the 
depletion of mtDNA are able to cause alterations in the global DNA methylation status of the 
cell lines (Figure 19 A).  
In the haplogroup analysis (when we compare the global 5-mC levels between the cell lines 
with mtDNA belonging to different haplogroup) (Figure 19 B) and normalizing the data to 
haplogroup X (143B), the haplogroup J (CMPBR3) showed the highest DNA methylation level. 
The increase in the global 5-mC levels in the haplogroup J (CMPBR3) was statistically 
significant (p<0.01) comparing to the haplogroup X (143B). Additionally, the 143B Rho0 cell 
line, showed the lowest DNA methylation level, being the global 5-mC levels statistically 
significant lower than those in the haplogroup X (143B) (p<0.001); J (CMPBR3) (p<0.001) and 
H (Cy 24) (p<0.01) (Figure 19 B).  
The cybrid lines harbouring the mutation in the mtDNA ND1 gene showed no differences in the 
percentage of 5-mC compared and normalized to the Cy 24 (wt mtDNA) cell line. In the other 
hand, the cybrid line with mtDNA tRNA Leu (UUR gene mutation) (3243Cy 9.7) presented a 
statistically significant increase in the DNA methylation level, compared with the 3571Cy 1 
(p<0.001), 3571Cy 22 (p<0.001) and the Cy 24 (p<0.001) cell lines (Figure 19 C). Data were 
normalized for Cy 24 cell line.  
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Figure 19. Analysis of DNA methylation status. A. Overview of global percentage of 5-mC in all cell lines compared with 143B 
cell line. B. Analysis of percentage of 5-mC in cell lines harbouring mtDNA belonging to different haplogroups (143B- haplogroup 
X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0). C. Analysis of percentage of 5-mC in cell lines harbouring mtDNA 
belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 22 and 3243Cy 9.7). 5-mC 
indicates 5-methylcytosine. Data correspond to three biological experiments done in triplicates. Bars, standard deviation; columns, 
mean. The asterisks indicates the level of statistical significance (** p<0.01 and ***p<0.001). Data were subjected to one-way 
ANOVA and a posterior Bennett and Tukey test. 
4.7.2 Real time PCR for genes involved in the methylation cycle and DNA 
methyltransferases.  
4.7.2.1 GNMT, MAT1A, MAT2A and MAT2B genes mRNA expression 
levels 
Trying to unveil the possible causes for the differences in the methylation pattern between the 
cell lines, we accomplished an evaluation of the mRNA levels, by real time PCR, for four of the 
genes involved in the methylation cycle (GNMT, MAT1A, MAT2A and MAT2B) as well as two 
DNA methyltransferases (DNMT1 and DNMT3B).  
Concerning GNMT gene expression, a statistically significant decrease were observed in the 
cell lines, harbouring mtDNA belonging to different haplogroups and/or different mtDNA  
mutations, compared with the parental cell line (143B) (Figure 20 A).   
When the mRNA levels were normalized for haplogroup X (143B), the haplogroups J 
(CMPBR3), H (Cy 24) and the 143B Rho0 cell line showed a statistically significant decrease in 
the GNMT gene expression compared with the haplogroup X (143B) [X (143B) vs J (CMPBR3) 
p<0.001; X (143B) vs H (Cy 24) p<0.01 and X (143B) vs 143B Rho0 p<0.01) (Figure 29 B).  
In the cell lines harbouring mutations in mtDNA, no statistically significant differences were 
observed concerning the cybrid cell lines displaying the mtDNA ND1 gene mutation, compared 
and normalized for Cy 24 (wt mtDNA) cell line. However the 3243Cy 9.7 cell line presented a 
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statistically significant increase (p<0.05) in the GNMT gene mRNA expression level compared 
with 3571Cy 1 cell line that presented the lowest GNMT gene expression (Figure 20 C).  
 
 
Figure 20. Real time PCR analysis for GNMT gene. A. Overview of GNMT gene mRNA levels in all the cell lines compared with 
143B cell line. B. Analysis of GNMT gene mRNA levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- 
haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of GNMT 
gene mRNA levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 
22 and 3243Cy 9.7), normalized to Cy 24 cell line. RQ indicates relative quantification. Data is normalized for HPRT gene 
expression and correspond to 3 experimental replicas. Bars, standard deviation; columns, mean. The asterisks indicates the level 
of statistical significance (*p<0.05; ** p<0.01 and ***p<0.001). Data were subjected to one-way ANOVA and a posterior Bennett 
and Tukey test. 
When the MAT1A mRNA levels were evaluated, an extremely low MAT1A gene expression 
level was observed in all cell lines. However, a statistically significant decrease in the mRNA 
levels of this gene was observed in all cell lines compared with the parental cell line (143B). 
(Figure 21 A).  
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Concerning the haplogroups analysis, the haplogroup J (CMPBR3), H (Cy 24) and the143B 
Rho0 cell line presented a statistically significant decrease in the MAT1A gene mRNA level, 
when compared and normalized to haplogroup X (143B) [X (143B) vs J (CMPRB3) p<0.05; X 
(143B) vs H (Cy 24) p<0.01 and X (143B) vs 143B Rho0 p<0.001] (Figure 21 B).  
When the MAT1A mRNA levels were normalized for the Cy 24 (wt mtDNA) cell line, all cell 
lines with mtDNA mutations showed a statistically significant reduction in the MAT1A gene 
expression, compared with Cy 24 cell line (Cy 24 vs 3571Cy 1 p<0.001; Cy 24 vs 3571Cy 22 
p<0.001 and Cy 24 vs 3242Cy 9.7 p<0.001) (Figure 30 C). 
 
Figure 21. Real time PCR analysis for MAT1A gene. A. Overview of MAT1A gene mRNA levels in all cell lines compared with 
143B cell line. B. Analysis of MAT1A gene mRNA levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- 
haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of MAT1A 
gene mRNA levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 
22 and 3243Cy 9.7), normalized to Cy 24 cell line. RQ indicates relative quantification. Data is normalized for HPRT gene 
expression and correspond to 3 experimental replicas. Bars, standard deviation; columns, mean. The asterisks indicates the level 
of statistical significance (*p<0.05; ** p<0.01 and ***p<0.001). Data were subjected to one-way ANOVA and a posterior Bennett 
and Tukey test. 
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MAT2A mRNA levels were evaluated in all the cell lines and no statistically significant 
alterations in the MAT2A gene expression were observed compared with the parental cell line 
(143B) (Figure 22 A). However the same cell lines, 3571Cy 22 and 143B Rho0, that presented 
a statistically significant reduction in the MAT1A gene expression, presented an increased, 
although not statistically significant, in the MAT2A mRNA levels. The 3571Cy 22 and the 143B 
Rho0 cell lines had the tendency to show an inverse relationship between the expression of the 
MAT1A and MAT2A genes (Figure 22 B and C).  
Concerning the haplogroup analysis, no statistically significant differences were also observed 
between the cell lines harbouring mtDNA belonging to different haplogroups (Figure 22 B). 
In the analysis of the cell lines with mutations in mtDNA, the 3571Cy 22 cell line showed a 
statistically significant higher MAT2A gene expression compared with  the Cy 24 (p<0.05), 
3571Cy 1 (p<0.01) and 3243Cy 9.7 (p<0.05) cell lines (Figure 22 C).  
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Figure 22. Real time PCR analysis for MAT2A gene. A. Overview of MAT2A gene mRNA levels in all cell lines compared with 
143B cell line. B. Analysis of MAT2A gene mRNA levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- 
haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of MAT2A 
gene mRNA levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 
22 and 3243Cy 9.7), normalized to Cy 24 cell line. RQ indicates relative quantification. Data is normalized for HPRT gene 
expression and correspond to 3 experimental replicas. Bars, standard deviation; columns, mean. The asterisks indicates the level 
of statistical significance (*p<0.05 and ** p<0.01). Data were subjected to one-way ANOVA and a posterior Bennett and Tukey 
test. 
Statistically significant variations in the MAT2B gene expression were observed between the 
cell lines harbouring mtDNA belonging to different haplogroups and/or different mtDNA 
mutations when compared with the 143B cell line (Figure 23 A). 
When the MAT2B gene mRNA levels were normalized for haplogroup X (143B), the haplogroup 
J (CMPBR3) presented the highest MAT2B gene expression and this difference was 
statistically significant from haplogroup X (143B) (p<0.05), and the haplogroup H (Cy24) 
(p<0.001). The haplogroup H (Cy 24) presented the lowest MAT2B gene expression level and 
this difference was statistically significant comparing with the haplogroup X (143B) (p<0.01) 
and with the 143B Rho0 (p<0.001) cell line. No differences in MAT2B gene mRNA expression 
level were observed between the 143B and 143B Rho0 cell lines (Figure 23 B).  
In the analysis of the cybrid lines with mtDNA mutations, all the cell lines showed a statistically 
significant alterations in the MAT2B gene mRNA levels compared to Cy 24 cell line. The 
3571Cy 22 and 3243Cy 9.7 cell lines presented a statistically significant increase in the MAT2B 
gene expression when compared and normalized to Cy 24 cell line (Cy 24 vs 3571Cy 22 
p<0.001; Cy 24 vs 3243Cy 9.7 p<0.001). The cell line displaying an mtDNA tRNA Leu (UUR) gene 
mutation (3243Cy 9.7) revealed the highest MAT2B gene mRNA expression level and this 
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difference was statistically significant comparing with the 3571Cy 1 (p<0.001) and 3571Cy 22 
(p<0.001) cell lines. Additionally the 3571Cy 1 cell line showed the lowest MAT2B gene 
expression level , being this difference statistically significant comparing with 3571Cy 22 cell 
line (p<0.001) (Figure 23 C).  
 
 
Figure 23. Real time PCR analysis for MAT2B gene. A. Overview of MAT2B gene mRNA levels in all cell lines compared with 
143B cell line. B. Analysis of MAT2B gene mRNA levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- 
haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of MAT2B 
gene mRNA levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 
22 and 3243Cy 9.7), normalized to Cy 24 cell line. RQ indicates relative quantification. Data is normalized for HPRT gene 
expression and correspond to 3 experimental replicas. Bars, standard deviation; columns, mean. The asterisks indicates the level 
of statistical significance (*p<0.05; ** p<0.01 and ***p<0.001). Data were subjected to one-way ANOVA and a posterior Bennett 
and Tukey test. 
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4.7.2.2 DNA methyltransferases: DNMT1 and DNMT3B genes mRNA 
expression levels  
In order to verify if the presence of mtDNA mutations/variants as well as absence of mtDNA 
have some effect on the expression of DNA methyltransferases (DNMTs) we performed an 
evaluation of the mRNA levels of two DNMTs: DNMT1 “maintenance methyltransferase” and 
DNMT3B “de novo methyltransferase”.  
Concerning the DNMT1 mRNA expression levels, statistically significant alterations were 
observed, either in cell lines harbouring mtDNA belonging to different haplogroup and in cell 
lines harbouring different mtDNA mutations, compared with the parental cell line (143B) (Figure 
24 A). 
When normalized for the mRNA levels of the haplogroup X (143B), the haplogroup J (CMPBR3) 
showed the lowest DNMT1 gene expression and presented a statistically significant differences 
from the haplogroup H (Cy 24) (p<0.05), X (143B) (p<0.001) and the 143B Rho0 cell line 
(p<0.001). Additionally the haplogroup H (Cy 24) showed a statistically significant decrease 
(p<0.05) in the DNMT1 gene expression compared to haplogroup X (143B) (Figure 24 B). 
Regarding the cell lines harbouring mtDNA mutations, all of them showed a statistically 
significant reduction in the DNMT1 gene mRNA levels when compared and normalized to Cy 
24 cell line [Cy 24 vs 3571Cy 1 (p<0.01); Cy 24 vs 3571Cy 22 (p<0.05) and Cy 24 vs 3243Cy 
9.7 (p<0.01)] (Figure 24 C). 
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Figure 24. Real time PCR analysis for DNMT1 gene. A. Overview of DNMT1 gene mRNA levels in all cell lines compared with 
143B cell line. B. Analysis of DNMT1 gene mRNA levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- 
haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of DNMT1 
gene mRNA levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 
22 and 3243Cy 9.7), normalized to Cy 24 cell line. RQ indicates relative quantification. Data is normalized for HPRT gene 
expression and correspond to 3 experimental replicas. Bars, standard deviation; columns, mean. The asterisks indicates the level 
of statistical significance (*p<0.05; ** p<0.01 and ***p<0.001). Data were subjected to one-way ANOVA and a posterior Bennett or 
Tukey test. 
With the purpose to understand if the cell lines in study display some alteration in the 
expression of the DNMTs with activity of “de novo methyltransferase” we decided to study the 
DNMT3B gene mRNA expression levels, by real time PCR.  
Regarding the DNMT3B gene expression, the cell lines displaying different mtDNA mutations 
(3243Cy 9.7, 3571Cy 1 and 3571Cy 22) revealed a statistically significant differences 
compared with the parental cell line (143B) (Figure 25 A).  
The haplogroup H (Cy 24) showed the highest DNMT3B gene expression level and this 
difference was statistically significant comparing with the haplogroup J (CMPBR3) (p<0.05). 
The data were normalized for to haplogroup X (143B) (Figure 25 B). 
Concerning the cell lines with mtDNA mutations, all of them revealed a statistically significant 
decrease in the expression of DNMT3B gene when compared and normalized to Cy 24 cell line 
[Cy 24 vs 3571Cy 1 (p<0.001); Cy 24 3571Cy 22 (p<0.001) and Cy 24 vs 3243Cy 9.7  
(p<0.001)] (Figure 25 C). 
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Figure 25. Real time PCR analysis for DNMT3B gene. A. Overview of DNMT3B gene mRNA levels in all cell lines compared 
with 143B cell line. B. Analysis of DNMT3B gene mRNA levels in cell lines harbouring mtDNA belonging to different haplogroups, 
(143B- haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. C. Analysis of 
DNMT3B gene mRNA levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 
1, 3571Cy 22 and 3243Cy 9.7), normalized to Cy 24 cell line. RQ indicates relative quantification. Data is normalized for HPRT 
gene expression and correspond to 3 experimental replicas. Bars, standard deviation; columns, mean. The asterisks indicates the 
level of statistical significance (** p<0.01 and ***p<0.001). Data were subjected to one-way ANOVA and a posterior Bennett and 
Tukey test. 
4.7.3 Evaluation of 5-hydroxymethylcytosine  
With the purpose to evaluated if the global levels of 5-hydroxymethylcytosine (5-hmC), also 
change in consequence of mtDNA mutations/variants (143B, CMPBR3, 3243Cy 9.7, 3571Cy 
1, 3571Cy 22 and Cy 24) as well as absence of mtDNA (143B Rho0), we assessed the global 
percentage of 5-hmC in the different cell lines in study. 
Regarding the global levels of 5-hmC no statistical differences were observed between all the 
cell lines compared with the parental cell line (143B) (Figure 26 A).  
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However, when normalized to haplogroup X (143B), the haplogroup J (CMPBR3) showed a 
reduction, although not statistically significant in the percentage of 5-hmC compared with the 
haplogroup X (143B) (Figure 26 B). 
The cell lines harbouring the mtDNA ND1 gene mutation (3571Cy 1 and 3571Cy 22), showed 
no alteration in the levels of 5-hmC, in contrast, the 3243Cy 9.7 cybrid cell line presented a 
reduction, although not statistically significant, in the percentage of 5-hmC, when compared 
and normalized for the Cy 24 cell line (Figure 26 C).  
 
 
Figure 26. Analysis of global levels of 5-hydroxymethylcytosine. A. Overview of 5-hmC in all cell lines. B. Analysis of 5-hmC 
in cell lines harbouring mtDNA belonging to different haplogroups (143B- haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup 
H and 143B Rho0). C. Analysis of 5-hmC in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations 
(3571Cy 1, 3571Cy 22 and 3243Cy 9.7). 5-hmC indicates 5-hydroxymethylcytosine. Data correspond one experiment done in 
duplicates. Bars, standard deviation; columns, mean. Data were subjected to one-way ANOVA and a posterior Bennett and Tukey 
test. 
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4.8 Protein lysine acetylation and ACL protein expression 
Considering one important post-translational modification, protein acetylation, we decided to 
study in detail if the mtDNA mutations/variants (143B, CMPBR3, 3243Cy 9.7, Cy 24 3571Cy 1 
and 3571Cy 22) as well as absence of mtDNA (143B Rho0), leads to changes in the level of 
acetylation of proteins. To reach our purpose we performed a western blot analysis, using an 
antibody against acetylated lysines, in all cell lines. 
Indeed, our results, by analysis of the intensity of the bands, showed differences in the pattern 
of acetylated lysines of proteins. The differences were more highlighted between the 143B Rho0 
and the parental cell line (143B), specifically in the proteins with a molecular mass lower than 
50 kDa (Figure 27). Compared with the 143B, in overall, the 143B Rho0 cell line showed a 
decrease in the intensity of WB (corresponding to a decrease in acetylation level of the proteins) 
(Figure 27).  
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Analysis of acetylated lysines. Western blot analysis for acetylated lysines proteins and β-Actin protein as an 
endogenous control in all cell lines. 
New questions arose from the analysis of these results, such as, the cause of these differences 
in the acetylation levels of proteins between cell lines. Trying to answer this question we 
performed a western blot analysis for the ATP citrate lyase (ACL) protein levels. ACL protein is 
involved in the synthesis of Acetyl-CoA that is important for activity of enzymes involved in 
protein acetylation.   
No statistically significant variations were observed between the different cell lines concerning 
the ACL protein expression, compared with the parental cell line (143B) (Figure 28A and B).  
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In the haplogroup analysis once again no statistically significant variations were observed. 
Although the haplogroup J (CMPBR3), H (Cy 24) and the 143B Rho0 cell lines tend to present 
an increase in ACL protein expression levels when compared and normalized to the haplogroup 
X (143B) (Figure 28C). The results obtained for the cybrids with mtDNA mutations revealed no 
differences in ACL protein expression levels, when compared and normalized to Cy 24 cell line 
(Figure 28D).  
 
Figure 28. Analysis of ACL protein expression. A. western blot analysis for the ACL protein and β-Actin protein as an 
endogenous control. B. Overview of ACL protein expression levels in all cell lines, normalized to 143B cell line. C. Quantification 
of ACL protein levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- haplogroup X; CMPBR3- 
haplogroup J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. D. Quantification of ACL protein expression 
levels in cell lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 22 and 3243Cy 
9.7), normalized to Cy 24 cell line. A representative immunoblot of three experiments is shown. Data are expressed as density of 
ACL band per the density of the β-actin. Bars, standard deviation; columns, mean. Data were subjected to one-way ANOVA and 
a posterior Bennett and Tukey test. 
4.9 Study of acetylated proteins 
So far, the results of this work demonstrate the presence of differences in the level of acetylated 
lysines proteins between the cell lines. Since the most pronounced differences were observed 
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between the parental cell line (143B) and the143B Rho0 cell line we decided to perform a more 
detailed analysis in order to reveal these differences and also to identify which proteins were 
differentially acetylated between these two cell lines. In order to accomplish this aim we decided 
to perform a two dimensional gels (2-D gels) analysis in the two cell lines and a posterior 
analysis for acetylated proteins and coloration of the 2-D gels with coomassie blue.   
We started by the evaluation of the differences between the intensity of the spots in the 2-D 
gels of the two cell lines and we were able to identify twenty one spots with differences in the 
intensity or presence/absence between the two cell lines. The 143B Rho0 cell line showed a 
global decrease in spots intensity with some exceptions, namely in the spot identified as 13. 
Each spot with different intensity or presence/absence between the two cell lines were 
confirmed in at least two experiments (Figure 29 A and B). 
 
Figure 29. Analysis of acetylated protein levels. A. Two dimensional analysis for the acetylated proteins in 143B cell line. B. 
Two dimensional analysis of acetylated proteins levels in 143B Rho0 cell line. A representative immunoblot of three experiments 
is shown.  
With the purpose to identify which protein(s) corresponding to each spot, we performed a 
coloration of the 2-D gels with coomassie blue (Figure 30) and we were able to identify all the 
twenty one spots observed in three immunoblots performed for each cell line in the gel stained 
with coomassie blue (Figure 31). Additionally, comparing the 21 selected 2-D gels spots with 
the spots from coomassie blue gels, no relevant differences were observed concerning the 
protein expression between the two cell lines. These results indicate that the differences 
observed in 2-D gels were related with differences in the acetylation levels and not with 
alteration in the expression of these proteins (Figure 30). 
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After the identification of the spots we performed a mass spectrometry analysis to identify each 
protein from behind each spot. It was possible to identify proteins in all samples with statistical 
confidence, except in sample 6. In the samples 3, 14, 15 it was possible to identify two proteins 
and in the sample 19 it was possible to identify three proteins in the same spot (see table 3). 
 
Figure 30. Analysis of two dimensional gels stained with coomassie blue for the 143B and 143B Rho0 cell lines. A. Two 
dimensional analysis for the total cell lysates of the 143B cell line. B. Two dimensional analysis for the total cell lysates of the 143B 
Rho0 cell line.  A representative immunoblot of two experiments is shown.  
 
Figure 31. Identification of proteins in two dimensional gel stained with coomassie blue corresponding to the 143B 
sample. 1- 40S ribosomal protein SA (RPSA); 2- L-lactate dehydrogenase B (LDHB); 3- Lupus La protein (SSB) and  alpha enolase 
(ENOI); 4, 5, 6- Transketolase (TKT); 7,8- Pyruvate kinase (PKM); 9, 11- Phosphoribosylaminoimidazole carboxylase (PAICS); 
10- Alpha-enolase (ENOI); 12- Annexin A2 (ANXA2); 13-Glyceraldehyde-3-phosphate dehydrogenase (GAPDH); 14- X-ray repair 
complementing defective repair in Chinese hamster cells 6 (ku autoantigen 70kDa) and Heat shock protein 75 kDa (TRAP1); 15-
X-ray repair cross-complementing protein (XRCC) and Heat shock protein 75kDa (TRAP1); 16- Isoform 2 of Rab GDP dissociation 
inhibitor beta (GDI2); 17- Actin, cytoplasmic 1 (ACTB); 18- Elongation factor 2 (EEF2); 19- F-actin-capping protein subunit alpha-
1(CAPZA1), isoform 2 of Pyruvate dehydrogenase E1 (PDHB) and 60s acidic ribosomal protein (RPLP0); 20- Eukaryotic translation 
initiation factor 3 subunit I (eIF3I); 21- Eukaryotic initiation factor 4A-I(eIF4AI). 
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Table 5. List of proteins identified by mass spectrometry 
kDa indicates kilo Daltons 
In order to confirm that the differences observed are due to differences in acetylation and not 
in the protein levels, we performed a western blot analysis for some of the proteins identified in 
the mass spectrometry analysis. The protein levels of Glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH), alpha enolase (ENOI) and eukaryotic initiation factor 4A I (eIF4AI) 
were quantified (data not shown) and no differences were found in the protein levels between 
the 143B and 143B Rho0  or all other cell line (Figure 32). 
Regarding the differences observed in the acetylation levels of the identified proteins, we 
decided to confirm some of these data with another technique and an immunoprecipitation for 
acetylated lysines was performed. After the immunoprecipitation of acetylated proteins, using 
the antibody against acetylated lysines, an immunoblot with an antibody against GAPDH 
protein, previous identified as the spot number 13, was performed in the two cell line. 
Indeed, we were able to confirm the increase level in acetylation of GAPDH protein presented 
in the 143B Rho0 cell line (Figure 33).  
 
Figure 32. Analysis for the eIF4AI, GAPDH and ENOI proteins. Western blot analysis for the eukaryotic initiation factor 4AI 
(eIF4AI), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alpha enolase (ENOI) and α-tubulin as an endogenous 
control in all cell lines. 
 
 
Figure 33. Immunoprecitation for Glyceraldehyde-3-phosphate dehydrogenase. IP indicates immunoprecipitates; Ctrl. 
Control; Lys.-Total cell lysates; The control was performed using an polyclonal antibody against TOM-20. 
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4.10 Sirt3 and SOD-2 protein expression, regulation of activation 
Since the levels of acetylated lysines can be regulated by the activity of protein deacetylases, 
we decided to study the expression levels of one of the cell deacetylases, and we decided to 
choose Sirt3, since a Sirt3 acts on mitochondrial proteins.  
With the purpose to verify if mtDNA mutations/variants as well as absence of mtDNA, affects 
the Sirt3 protein expression and if Sirt3 protein levels leads to changes in SOD-2 protein 
expression (SOD-2 is a Sirt3 target protein) and activity (SOD-2K68), whose deacetylation its 
related with activation, we evaluated by western blot, the protein levels of Sirt3, SOD-2 and 
SOD-2k68.  
No statistically significant differences in the Sirt3 protein expression levels, were observed 
between the cell lines compared with parental cell line (143B) (Figure 34 A and B).  
When normalized for Cy 24 (wt mtDNA) cell line, the cybrid lines with mtDNA ND1 gene 
mutation, showed no statistically significant differences in Sirt3 protein expression, by contrast 
the 3243Cy 9.7 cell line exhibited an increased in Sirt3 protein expression level, being this 
difference statistically significant when compared with 3571Cy 1 (p<0.05) and 3571Cy 22 
(p<0.01) cell lines.  
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Figure 34. Analysis of Sirt3 protein expression. A. Western blot analysis for Sirt3 protein, and β-Actin protein as an endogenous 
control. B. Overview of Sirt3 protein expression levels in all cell lines normalized to 143B cell line. C. Quantification of Sirt3 protein 
expression levels in cell lines harbouring mtDNA belonging to different haplogroups, (143B- haplogroup X; CMPBR3- haplogroup 
J; Cy 24-haplogroup H and 143B Rho0), normalized to 143B cell line. D. Quantification of Sirt3 protein expression levels in cell 
lines belonging to the same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 22 and 3243Cy 9.7), 
normalized to Cy 24 cell line. A representative immunoblot of three experiments is shown. Data are expressed as density of Sirt3 
band per the density of the β-actin. Bars, standard deviation; columns, mean. The asterisks indicates the level of statistical 
significance (*p<0.05; ** p<0.01). Data were subjected to one-way ANOVA and a posterior Bennett and Tukey test. 
Concerning SOD-2 (a Sirt3 target) protein expression, although the 143B Rho0 cell line showed 
a slight increase in Sirt3 protein expression level, a statistically significant increased (p<0.05) 
in SOD-2 protein expression and a statistically significant decrease (p<0.01) in SOD-2k68 
protein level were observed, when compared with the parental cell line (143B) (Figure 35 C). 
Additionally, all cell lines showed an increase, not statistically significant, in SOD-2 protein 
expression compared with the 143B cell line (Figure 35 A and B).  
When normalized for Cy 24 (wt mtDNA) cell line, the cybrid lines with mtDNA mutations showed 
no statistically significant alterations in SOD-2 protein expression (Figure 35 D).  
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Concerning the activity of SOD-2 (SOD-2k68) all cell lines, with the exception of CMPBR3 and 
the 3243Cy 9.7 cell lines, exhibited a statistically significant decrease in the acetylation level of 
SOD-2k68 compared with parental cell line (143B) (Figure 20 A and B).  
Moreover, in the haplogroups analysis we observed a statistically significant decrease in the 
acetylation level of k68 at SOD-2 in the haplogroup H (Cy 24) (p<0.001) and 143B Rho0 cell 
line (p<0.001) compared to the haplogroup X (143B) and J (CMPBR3) when normalized for the 
haplogroup X (143B) (Figure 34 C).  
In the analysis of cybrid lines harbouring mtDNA mutation, all cybrid cell lines showed a 
statistically significant increase in acetylation of k68 at SOD-2 when compared and normalized 
to Cy 24 cell line [Cy 24 vs 3571Cy 1 (p<0.001); Cy 24 vs 3571Cy 22  (p<0.05) and Cy 24 vs 
3243Cy 9.7 (p<0.001)] (Figure 35D). Moreover, the 3243Cy 9.7 exhibited the highest 
acetylation levels of SOD-2k68, and exhibited a statistically significant difference when 
compared with the 3571Cy 1 (p<0.001) and the 3571Cy 22 (p<0.001) cell lines. The cell lines 
presenting mtDNA ND1 gene mutation revealed statistically significant differences between the 
level of acetylation of SOD-2k68, being the 3571Cy1 the cell line the one that exhibit a 
statistically significant increase in the acetylation of SOD-2k68 compared to the 3571Cy 22 
(p<0.001) cell line (Figure 35 D). 
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Figure 35. Analysis of SOD-2 and SOD-2K68 protein expression. A. western blot analysis for proteins SOD-2, SOD-2K68 and 
β-Actin protein as an endogenous control. B. Overview of SOD-2 and SOD-2K68 protein expression levels in all cell lines 
normalized to 143B cell line. C. Quantification of SOD-2 and SOD-2K68 protein expression levels in cell lines harbouring mtDNA 
belonging to different haplogroups, (143B- haplogroup X; CMPBR3- haplogroup J; Cy 24-haplogroup H and 143B Rho0), 
normalized to 143B cell line. D. Quantification of SOD-2 and SOD-3K68 protein expression levels in cell lines belonging to the 
same haplogroup without (Cy 24) and with mtDNA mutations (3571Cy 1, 3571Cy 22 and 3243Cy 9.7), normalized to Cy 24 cell 
line. A representative immunoblot of three experiments is shown. Data are expressed as density of SOD-2 or SOD-2k68 band per 
the density of the β-actin. Bars, standard deviation; columns, mean. The asterisks indicates the level of statistical significance 
(*p<0.05; ** p<0.01 and ***p<0.001). Data were subjected to one-way ANOVA and a posterior Bennett and Tukey test. 
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5.1 Mitochondrial energy metabolism and the epigenetics  
Many vital cellular parameters are controlled by mitochondria, namely, the regulation of energy 
production (ATP), β-oxidation of fatty acids, metabolism of amino acids and lipids, SAM 
production, modulation of oxidation-reduction (redox) states, regulation of the NAD+/NADH and 
FAD+ /FADH2 ratios, generation of ROS and contribution to cytosolic biosynthetic precursors 
such as cytosolic acetyl-CoA. Changes in these parameters can impinge on biosynthetic 
pathways, cellular signal transduction pathways, transcription factors and chromatin structure 
to shift the cell from a quiescent, differentiated state to an actively proliferating one (Desler and 
Marcker, 2011; Wallace, 2012; Wallace and Fan, 2010). The circular mtDNA is more 
susceptible to DNA damages in comparison to nDNA. Importantly, mtDNA molecules are not 
protected by histones, they are supported with only “rudimentary” DNA repair and are localized 
in close proximity to the ETC which continuous generates ROS. Thus, the mutation rate of 
mtDNA has been reported being up to 10-15 folds higher than that observed in nDNA in 
response to DNA damaging agents (Desler and Marcker, 2011). The mitochondrial activity is 
largely dependent on environmental availability of nutrients and their conversion to usable 
energy that takes place by the conversion, by mitochondrion and glycolysis, of energy rich 
compounds, such as carbohydrates and fats, into ATP, acetyl-CoA, SAM, and NADH. ATP, 
acetyl-CoA, SAM, and NAD+/NADH ratio, in turn, are the high-energy substrates for protein 
(including histones) phosphorylation, acetylation and deacetylation reactions, and DNA and 
protein methylation, thus contributing to regulation of several pathways and epigenetic process 
of chromatin remodelling (Wallace and Fan, 2010). 
Mutations in the mtDNA, most of the time induce defects in OXPHOS. Mitochondrial 
dysfunction, and especially mitochondrial dysfunction caused by mutations in mtDNA have 
been implicated in a wide range of age related pathologies, including cancer, diabetes and 
degenerative disorders (Figure 36A and B) (Tuppen et al., 2010). Indeed, mitochondrial gene 
defects can result in virtually all of the symptoms associated with the common complex 
diseases, confirming the importance of mitochondrial bioenergetics in health. In addition, it was 
reported that mtDNA variants, are able to regulate several intracellular functions and to 
influence global methylation levels and nuclear gene expression, having a role in human aging 
and longevity. (D’Aquila et al., 2013). Either way, OXPHOS efficiency and/or the activation of 
signalling pathways, regulates the substrate levels needed for PTMs and epigenetic regulation 
and thus the epigenetic landscape of the cell (DeBerardinis and Thompson, 2012; Lu and 
Thompson, 2012). 
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The epigenome has been hypothesized to provide the interface between the environment and 
the regulation of nDNA gene expression. Indeed, epigenetic mechanisms are essential for the 
normal development and maintenance of tissue-specific gene expression patterns in mammals. 
Disruption of epigenetic processes can lead to altered gene expression seen in a variety of 
human disorders including aging, cancer and neurodegenerative diseases among others 
(Hanahan and Weinberg, 2011). In fact, global changes in the epigenetic landscape of the cell 
are a hallmark of cancer (Hanahan and Weinberg, 2011). Additionally, the similarity in 
symptoms between mitochondrial and epigenomic diseases suggest that they possible have a 
common pathophysiology (Hanahan and Weinberg, 2011; Wallace, 2009).  
 
 
 
 
 
 
 
 
A 
83 
 
 
Figure 36. Genotype: phenotype correlations in human mitochondrial disease. A .The circular, double-stranded human 
mitochondrial genome is depicted with sites of common mtDNA mutations highlighted. Associated clinical presentations are also 
highlighted. CPEO, chronic progressive external ophthalmoplegia; LHON, Leber hereditary optic neuropathy; LS, Leigh syndrome; 
MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; MERRF, myoclonic epilepsy and 
ragged red fibres; MILS, maternally inherited Leigh syndrome; NARP, neurogenic weakness, ataxia, and retinitis pigmentosa; PS, 
Pearson syndrome (Tuppen et al., 2010). B. Human mitochondrial genome showing several mutations described  in different 
malignancies (adapted from Chatterjee et al., 2006). 
5.2 Cell lines  
Several studies have demonstrated a relationship of defective complex I and OXPHOS, with 
the mtDNA ND1 gene mutations; however, an epigenetic analysis has never been done, to our 
knowledge. Inactivation of complex I, the most studied OXPHOS complex and one of the most 
commonly affected in human tumours, would allow us to understand the relation between 
complex I deficiency and PTMs including epigenetics changes. 
On the other hand, it would be interesting to compare the effect of an OXPHOS dysfunction 
due to defect in a specific mitochondrial complex with that of a defect in all the complex. 
By using cybrid cell lines with different mtDNA mutations/variants, wt mtDNA, as well as a cell 
line without mtDNA, we were able disclose a putative role of mtDNA mutations in cell 
metabolism, in OXPHOS dysfunction as well as in cell epigenetics landscape regulation. 
B 
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With our cell line models, cell lines harbouring wt mtDNA belonging to different haplogroups 
(143B, CMPBR3 and Cy24), cell lines with different mtDNA mutations (3243Cy 9.7, 3571Cy 1 
and 3571Cy 22) and a cell line without mtDNA (143B Rho0), we were able to study the effect 
of mitochondrial dysfunction, in a specific mitochondrial complex and as well as in all 
mitochondrial complex, on cell metabolism, on PTMs an epigenetic landscape changes and in 
gene expression changes.   
5.3 Complex I activity  
Complex I is the gatekeeper of the respiratory chain and catalyses the first step of NADH 
oxidation. Complex I activity elevates the NAD+/NADH ratio and translocates protons across 
the inner mitochondrial membrane, which ultimately leads to energy production. MtDNA 
mutations in genes encoding complex I subunits, including the mtDNA ND1 gene, are 
frequently found in a variety of malignancies (Chatterjee et al., 2006; Máximo et al., 2009).  
The NAD+/NADH redox balance are important for the activity of Sirtuins that use the NAD+ as 
a co-factor to deacetylate substrates ranging from histones to transcriptional regulators, and 
ultimately alters the acetylation status of the cell. Through this activity, several studies have 
been demonstrating that Sirtuins regulate important biological processes, such as apoptosis, 
cell differentiation, energy transduction or glucose homeostasis (Li and Kazgan, 2011). 
Furthermore, the mitochondrial complex I activity and NAD+/NADH balance, have been 
associated with cancer progression (Santidrian et al., 2013). However, it is largely unknown 
how alterations in complex I and in the cellular NAD+/NADH redox balance affect 
tumourigenesis and cancer progression. Recently, it was demonstrated that complementation 
of a truncated mutation in the gene encoding mitochondrial ND1, showed that a functional 
enzyme was required to perform the glycolytic shift during the hypoxia response and to induce 
a Warburg effect in vitro and in vivo, fostering cancer progression (Calabrese et al., 2013). 
In this study, we found that mtDNA mutations, absence of mtDNA or even mtDNA belonging to 
different haplogroups are able to affect mitochondrial complex I activity and induce 
mitochondrial dysfunctions. Actually, we found that cybrid cell lines with mutations in mtDNA 
ND1 gene (3571Cy 1 and 3571Cy 22) as well as in mtDNA tRNA Leu (UUR ) gene (3243Cy 9.7) 
exhibit a lower mitochondrial activity that of a cybrid cell line with wt mtDNA belonging to 
haplogroup H (Cy 24). Furthermore, we observed statistically significant differences, in complex 
I activity, between cell lines with wt mtDNA belonging to different haplogroups, suggesting that 
differences in OXPHOS activity exist between several mitochondrial variants. Nevertheless, 
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several studies, report contradictory results concerning the effect of mtDNA variants in 
OXPHOS efficiency. Actually, it has been reported that mtDNA molecules belonging to different 
haplogroups may differ in the degree of OXPHOS activity (Gómez-Durán et al., 2010; Hinttala 
et al., 2010; Pello et al., 2008), and in other hand there is also evidence that different mtDNA 
haplogroups may maintain similar efficiency in OXPHOS performance, through the fine-tuning 
of ROS production and mitochondrial biogenesis (Carelli et al., 2002).  
Cells depleted of mtDNA (143B Rho0) retain functional mitochondria, except lacking OXPHOS, 
because of the absence of all the mitochondrial encoded proteins. Indeed, by the analysis of 
our results, the 143B Rho0 cell line showed the lowest level of complex I activity. Interesting, 
143B Rho0 cell line showed similar complex I activity (lower, but not statistically significant) 
compared with the haplogroup X (143B), although lower than those of cell line lines from 
haplogroup H (Cy 24) and J (CMPBR3). These data suggest that haplogroup X is less efficient 
in complex I activity than haplogroups H and J.  
The 143B cell line, presented a decrease in the expression of mitochondria encoded proteins 
such as, COXII and ND1, analysed be western blot. This reduction in the protein levels may be 
responsible for the decrease in OXPHOS as well as in complex I activity.   
The complex I activity have been also proposed to have a central role in the regulation of 
longevity (Calabrese et al., 2013; Kayser et al., 2004). Additionally, different haplogroups have 
been related with regulation of lifespan (De Benedictis et al., 1999). The possible role played 
by mtDNA variants in longevity may be related with the complex I activity.  From our results, 
the haplogroup J (CMPBR3) and H (Cy 24) showed the higher complex I activity. Indeed 
mtDNA haplogroup J has been reported to increase the individual chance to attain longevity. 
To the best of our knowledge, the increase in complex I activity observed in different 
haplogroups and the link to longevity may be due to the increase the levels of NAD+. Actually, 
the NAD+ acts as co-factor of Sirtuins whose activity have been also related with the longevity 
(Brown et al., 2013; Domínguez-Garrido et al., 2009; Fontana et al., 2010; Kanfi et al., 2012). 
It is possible that these four matters, haplogroups, complex I activity, Sirtuins activity and 
longevity, are related, but at our knowledge there is no studies trying to relate this four matters. 
Regarding the cell lines with mutations in the mtDNA (3243Cy 9.7, 3571Cy 1 and 3571Cy 22), 
they showed a reduction in complex I activity, evidencing that the mutations in mtDNA ND1 
gene and mtDNA tRNA Leu (UUR) gene, commits the complex I activity.  
The ND1 3571InsC mutation, generates a premature stop codon at amino acid 101 of ND1 
protein, which, as consequence, will be truncated. The truncated protein is not assembled in 
complex I, thus the decrease in complex I activity observed in the cell lines displaying 3571InsC 
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mutation (3571Cy 1 and 3571Cy 22), results from a decrease in the incorporation of normal 
ND1 protein in complex I. In fact, we observed a reduction of ND1 protein expression levels in 
the cell lines harbouring the ND1 3571InsC mutation. This decreased in the incorporation of 
ND1 proteins result in complex I enzymatic deficiencies, that can be reflected in the decrease 
in complex I activity. Moreover some studies, reported that cell lines harbouring the mtDNA 
ND1 frame-shift mutation (3571InsC), exhibit complex I enzymatic deficiencies and reduced 
assembly of complex I (Porcelli et al., 2009). With the purpose to study if our cell lines 
harbouring the mtDNA ND1 frame-shift mutation (3571InsC) revealed differences in complex I 
assembly capacity, we performed the analysis of NDUFS3 (another complex I protein, encoded 
by nDNA) protein expression, and no differences were observed, between the cell lines with 
and without mtDNA ND1 gene mutation. This datum suggest that the mtDNA ND1 frame-shift 
mutations (3571InsC), does not change complex I assembly. Indeed, other studies used the 
complex I subunit NDUFS3 to monitor the progression of this subunit (ND1) into the mature 
holo-enzyme (Vogel et al., 2007). The absence of differences, between cell lines displaying 
and not displaying the mtDNA ND1 3571InsC mutation, in complex I assembly, may be due to 
the fact that our cell line have a maximum of 80% of heteroplasmic mtDNA ND1 frame-shift 
mutations (3571InsC).  
The decrease, in the complex I activity,  observed in the 3243Cy 9.7 cell line, is due to a mtDNA 
tRNA Leu (UUR) gene mutation which result in globally impairment of mitochondrial protein 
synthesis and affects all OXPHOS complexes containing mtDNA-encoded subunits (i.e., 
complexes I, III, IV, and V) (King et al., 1992). 
5.4 Global ATP levels  
Mitochondria are the principal generators of cellular ATP through OXPHOS, incorporating the 
electron-transferring respiratory chain (complexes I–IV) and the ATP synthase (complex V). 
Since mtDNA encodes for several key respiratory chain components, cells displaying different 
mtDNA may be present changes in their ATP levels (Figure 37). Indeed, we observed that 
mitochondria variants and mitochondria dysfunction caused either by mutations in mtDNA or 
absence of mtDNA exhibited alteration in OXPHOS activity, namely in the complex I activity.      
Differences, concerning ATP production capacity, have been reported in mitochondrial 
diseases cause by mtDNA mutations, as well as in individuals with mtDNA belonging to 
different haplogroups (presence of mitochondrial variants) (Bellizzi. et al., 2012; Kenney et al., 
2013; Naini and Sue, 2006). The differences in the ATP production reported in mitochondrial 
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diseases have been associated with mutations in nDNA and in mtDNA that cause respiratory 
chain dysfunction (Taylor and Turnbull, 2005). 
The haplogroup J has been reported as showing lower ATP production capacity compared with 
other haplogroups (Martínez-Redondo et al., 2010). This means that each haplogroup can have 
a unique bioenergetic signature. In fact, in our results, the haplogroup J presented a decrease, 
although not statistically significant, in the ATP levels. Interesting, this lower ATP production 
capacity does not correlate with complex I activity, since we observed an increase, although 
not statistically significant, in complex I activity. Since we performed an analysis of global ATP 
levels we cannot establish a link between the global ATP levels and the complex I activity. The 
mitochondrial ATP levels should be assessed in order to better clarify this findings. 
Nevertheless, some studies have found an association of the haplogroup J and alterations in 
the expression of uncoupling proteins. These proteins are responsible for the leak of protons 
generated in ETC and subsequent leads to a decrease of ATP and ROS production and to an 
increase in heat production (Martínez-Redondo et al., 2010; Wallace, 2005). It would be 
interesting to study the expression levels of some of these proteins, namely uncoupling protein 
2 (UCP2) (the best studied), in our cell lines, in order to verify if the absence of correlation 
between complex I activity and ATP production is related with changes in the expression of 
uncoupling proteins.  
Since mtDNA encodes for several key respiratory chain components, cells in which mtDNA has 
been depleted (143B Rho0 cells) are completely deficient in mitochondrial respiratory activity 
and thus in mitochondrial ATP synthesis. Indeed, 143B Rho0 cell line presented a decrease, 
although not statistically significant, in the ATP levels. Nevertheless, it has been reported that, 
the cells devoid of mtDNA, readjust their metabolism in order to improve ATP synthesis. These 
readjustments, involve, for instance, increased to glycolysis to function efficiently as an 
important source of cellular ATP, in the absence of OXPHOS  in Rho0 cells (Martinus et al., 
1993). 
The cell line with the mtDNA tRNA Leu (UUR) gene mutation (3243Cy 9.7) also presented a 
decrease, although not statistically significant, in the ATP levels. This cell line has a pronounced 
defect in the mitochondrial respiratory activity, due to the global impairment of the mitochondrial 
proteins that lead to alterations in all mitochondrial encoded OXPHOS complexes. Indeed, a 
number of studies, have been reporting a significant correlation between the reduction in ATP 
synthesis and the mutational load, in cells containing a mtDNA tRNA Leu (UUR)  gene mutation, 
related to the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-
like episodes) having the 3243A>G mutation (Cotán et al., 2011; Naini and Sue, 2006). 
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Figure 37. The role of the mitochondrial genome in energy generation. This highlights the importance of the mitochondrial 
genome in contributing polypeptide subunits to the five enzyme complexes that comprise the oxidative phosphorylation (OXPHOS) 
system within the inner mitochondrial membrane the site of ATP synthesis (Adapted from Taylor and Turnbull, 2005). 
5.5 Global metabolic profile of the cell lines 
The mitochondrial function is fundamental to metabolic homeostasis. In addition to converting 
the nutrient flux, through the OXPHOS, into the energy molecule ATP, the mitochondria 
generate intermediates for biosynthesis and ROS that serve as a secondary messenger to 
mediate signal transduction and metabolism. Alterations of mitochondrial function have been 
observed in various metabolic disorders, including aging and cancer, among other (Cheng and 
Ristow, 2013). However, the mechanisms responsible for mitochondrial changes and the 
pathways leading to metabolic disorders remain to be defined.  
So far, our results showed that mtDNA variants and mtDNA mutations presented alterations in 
the OXPHOS complex I activity and ATP production. In fact in cancer cells, the metabolic shift 
may be due to defects in OXPHOS that force cancer cells towards glycolysis (Máximo et al., 
2009). Conceptually, any alteration that disrupts the OXPHOS system will have a direct effect 
on the cell’s metabolism affecting the cell metabolic profile.  
The last 10 years have revealed a host of functions for metabolites and metabolic pathways 
that could not have been predicted from a conventional understanding of biochemistry. As a 
result it is no longer possible to view metabolism merely as a self-regulating network operating 
independent of other biological systems. Metabolism also affects cell signalling by providing 
substrates for PTMs that modulate protein trafficking, localization, and enzyme activity 
(DeBerardinis and Thompson, 2012).  
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In order to better understand the effect of mitochondrial variants and mitochondrial mutations 
in the metabolic alterations, we performed the global metabolic profile of the different cell lines 
in study. In fact, the cell lines analysed, presented changes in the levels of the metabolites 
involved in the PTMs, namely in acetylation (acetyl-CoA and CoA) in methylation (methionine 
and s-adenosylhomocysteine) compared with the parental cell line. Indeed, some studies have 
been reporting that mitochondrial diseases, as a results of mitochondrial dysfunction, can alter 
the function of several proteins via reversible or irreversible PTMs (Karve and Cheema, 2011; 
Ryan et al., 2012; Wu et al., 2010). Interestingly, the cell devoid of mtDNA (143B Rho0) does 
not showed a decrease in the levels of NAD+, although the absence of OXPHOS to regulates 
the NAD+/NADH ratio. Rho0 cells require the addition of pyruvate and other oxidants to growth 
media that are reduced by the plasma membrane electron transport contributing to maintain 
both growth and cytosolic NAD+ availability (Larm et al., 1994). Actually, NAD+ homeostasis, in 
Rho0 cells is required for Sirtuins activation because these cells maintain Sirtuin levels as wild 
type cells (Broadley et al., 2011; Crane et al., 2013). 
Regarding the redox sates, all cell lines evaluated showed an increase in the metabolites 
involved in the glutathione pathways, compared with the parental cell line. Since, the reduced 
glutathione (GSH) protects against oxidative damage, but is transformed in the process to its 
oxidized form (GSSG) (Schafer and Buettner, 2001) it is likely that mitochondria dysfunction 
caused, either by mutations in mtDNA (ND1 and tRNA Leu (UUR) mutations) or absence of mtDNA 
(143B Rho0), generate an increased amount of ROS and the GSH system in such instances is 
stressed to a higher degree than in normal mitochondrial function.  
5.6 DNA Methylation status of the cell lines   
The importance of the interaction between mitochondrial and nuclear genomes has also 
emerged from studies on epigenetic changes and, more specifically, on DNA methylation of 
cytosines. DNA methylation functions as a switch that turns relevant genes on and off, a 
mechanism that is crucial in development, differentiation and homeostasis (Deaton and Bird, 
2011). There is currently extensive ongoing research aiming the identification of specific 
changes in DNA methylation. Actually, DNA methylation has been confirmed as an important 
player in human disease, mediating genomic instability, silencing of tumour-suppressor genes 
and hyper-methylation of CpG island shores that may lead to the inception and progression of 
cancer (Baylin and Jones, 2011; Kriaucionis and Bird, 2003). 
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In fact, the efficiency of mitochondrial energy producing machinery and the mitochondrial 
metabolism can modulate the activity of MAT, the enzyme responsible for SAM synthesis from 
L-methionine and ATP (Pajares et al., 1992; Wallace, 2009; Wallace and Fan, 2010). Lastly, 
mitochondria contribute to epigenetics modification through the folate metabolism and the 
regulation of the metabolic switch between SAM and nucleotide synthesis through the one 
carbon Cycle. Besides, the dysfunction in mitochondrial activity may have direct effects on 
epigenetic markers and consequently, disrupt gene expression patterns and thus leading to 
changes in cellular functions. 
By the methylation analysis of the cell lines, we observed that mitochondrial variants and 
mitochondria dysfunction caused either by mutations in mtDNA or absence of mtDNA, 
presented alterations in the DNA methylation pattern, and also in the expression of genes 
involved in the one carbon metabolism. The cells devoid of mtDNA (143B Rho0) presented a 
reduction in the methylation levels and a decrease in the expression of the GNMT and MAT1A 
genes, but do not showed alterations in the levels of 5-hmC. The depletion of mtDNA leads to 
a blockage of TCA cycle, leading to the accumulation of succinate. 5-Hydroxymethylcytosine 
is an oxidative product of 5-mC, catalysed by the TET family of enzymes and their activity can 
be inhibited by the succinate. The accumulation of succinate observed in the 143B Rho0, may 
leads to the inhibition of TET proteins, leading to the hydroxylation of 5-mC to 5-hmC by a TET-
independent mechanism. However, oxidation of DNA has traditionally been considered a DNA 
damage event (Poulsen, 2005). Furthermore, oxidation of 5-mC appears to be a step in several 
active DNA demethylation pathways, which may be important for normal processes, as well as 
global hypomethylation during cancer development and progression (Kraus et al., 2012). 
In fact, the depletion of mtDNA in cancer cells with chemical or genetic treatments has been 
found to induce alterations in the DNA methylation pattern in 2-9% of the CpG islands surveyed. 
In most of the studies, with cells devoid of mtDNA, DNA hypomethylation is frequent finding. 
When mtDNA is reintroduced to the mtDNA-deficient cancer cell, 30% of the hypomethylated 
sitres become remethylated. This results indicated that there is a direct relationship between 
mitochondrial functional and epigenomic DNA methylation in cancer cells (Smiraglia et al., 
2008), however, we do not know the exactly mitochondria signal that triggers epigenetic 
changes in the nucleus. Turk et al., reported that the presence of 8-hydroxyl-2-deoxyguanosine 
(8-OH-dG) in CpG nucleotide, the most studied DNA base lesion induced by oxidative stress 
in aging, diminishes the ability of DNA methyltransferase to methylate the adjacent cytosine 
(Wei et al., 2001). In addition, Valinluck et al. demonstrated that the oxidation of guanosine in 
8-OH-dG and/or 5-mC in 5-hmC in a CpG dinucleotide significantly reduces the binding affinity 
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of methyl-CpG binding domain proteins (MBDs) to their recognition sequences, thus leading 
alterations in transcription (Turk et al., 1995). In addition, the intracellular redox state is also 
able to modulate the activity of MATs (Pajares et al., 1992; Valinluck et al., 2004).  
In other hand, we observed an increase in the 5-mC levels in the cell lines, harbouring the 
mtDNA tRNA Leu (UUR) gene mutation and in the haplogroup J (CMPBR3). The haplogroup J 
presented a decrease in the expression of GNMT, MAT1A and DNMT1, compared with other 
haplogroups, the only increase in the mRNA levels observed for the haplogroup J was the 
MAT2B gene. Bellizzi et al reported the increase in the methylation levels of haplogroup J 
compared with other haplogroups, but the reason for this increase in the level of 5-mC is not 
yet well understood (Bellizzi et al., 2012). Additionally, the haplogroup J have been extensively 
ascribed to low OXPHOS efficiency, given that the variants clustered in the J haplogroup mainly 
fall within mitochondrial complex I and complex III. Curiously, the cell line harbouring the 
mtDNA tRNA Leu (UUR) gene mutation, presented similar results for the expression on the 
evaluated genes, with exception of MAT1A gene, that was less expressed in the 3243Cy 9.7 
cell line, compared with the haplogroup J (CMPBR3). It is possible that the mechanism that 
allows the haplogroup J to increase the methylation levels were the same presented in the 
3243Cy 9.7 cell line. Indeed, we cannot establish a link between the changes in the pattern of 
DNA methylation and the expression of the evaluated genes, in spite of the two cell lines show 
an increase in the expression of the MAT2B gene.  
There are some possible explanations for the increase in the methylation levels observed in 
these cell lines, one of them is changes in the demethylation pathway. The 3243Cy 9.7 and the 
haplogroup J (CMPBR3) were the only cell lines that showed a reduction in the levels of 5-
hmC.  
For a better understanding of the reasons that leads to the increase in the DNA methylation 
levels of these two cell line, an evaluation of the activity of the enzymes involved in the one 
carbon metabolism should be performed and also an evaluation of the expression and activity 
of the TET enzymes. 
Alterations in the expression of genes involved in one carbon metabolism, were also observed 
in the cell lines displaying the mtDNA ND1 gene mutation (3571Cy 1 and 3571Cy 22), although 
these cell lines do not exhibited alterations in the 5-mC and 5-hmC levels. These observations 
reinforce the hypothesis that the alterations in the methylation pattern, due to alterations in 
mtDNA, may be related, not only with alterations in the gene expression, but also with other 
mechanisms.  
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Our data suggest that the mitochondrial dysfunctional can induce aberrant DNA methylation 
patterns, and in this way contrite to the aetiology of several diseases, such as cancer, aging 
and neurodegenerative disorders.   
5.7 Protein lysine acetylation and ACL protein expression  
The importance of acetylation is strengthened by studies showing that deregulated acetylation 
is tightly linked to major diseases, such as cancer. In addition, it is well accepted that cancer 
cells shows a metabolic profile different from that of normal cells (Xu et al., 2013). The 
mitochondrial alterations in cancer cell leads to unique metabolic signatures.   
To coordinate the metabolic network, a general coordinator should be associated with all or 
most of the metabolic enzymes, and it should sense metabolic signals. Such general 
coordinator of metabolism is so far not identified (Xu et al., 2013). Acetylation has the potential 
to meet both criteria, and thus to be a general coordinator of metabolism. All KATs use acetyl-
CoA as an acetyl group donor. Acetyl-CoA can be produced from glucose by the enzyme ACL, 
which generates acetyl-CoA from mitochondria-derived citrate. ACL dependent production of 
acetyl-CoA for lipogenesis is important for the proliferation of glycolytically converted tumour 
cells. Additionally, several studies, have been reporting that ACL is the major source of acetyl-
CoA for histone acetylation (Wellen et al., 2009; Zaidi et al., 2012).  
In fact, we observed differences between the cell lines in the pattern of acetylated lysines, 
which may be related with the differences in the mtDNA which assigned unique metabolic 
signatures, confirmed through the results from the global metabolic analysis. However, we do 
not observe differences in ACL protein expression levels between the cell lines. Indeed, the 
cell line devoid of mtDNA (143B Rho0), does not presented a decrease in ACL protein 
expression, although it showed a general reduction in the protein acetylation levels. These 
results may be related with the fact that the depletion of mtDNA results in oxidative stress 
causing increase in the lipid peroxidation, and to keep on balance the synthesis and 
degradation of fatty acids, they must maintain the levels of acetyl-CoA through ACL expression 
regulation. Actually, Delsite et al, reported the increase in peroxidation of lipids in cells depleted 
of mtDNA (Delsite et al., 2002). Additionally, to support this hypothesis, the activity of ACL 
enzyme should be determined, as well as the levels and activity of other proteins responsible 
for the synthesis of acetyl-CoA, namely the AceCS1 and AceCS2.  
Through mass spectrometry analysis, we were able to identified nineteen proteins showing 
differences in acetylation levels between the two cell lines analysed (143B and 143B Rho0). 
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We identified differences in acetylation levels in proteins involved in a number of cellular 
processes, including metabolism, protein synthesis, cellullar architecture and DNA repair.  
As mentioned above, protein acetylation can have numerous functional consequences 
including changes in: enzyme activation/inactivation; protein DNA interaction; protein stability; 
protein subcellular localization; and in specific functional complex formation (Figure 38).  The 
143B Rho0 cell line has a unique metabolic signature due to the absence of mtDNA, leading to 
alterations in metabolism and other cellular processes. Several studies have been reporting 
that mtDNA depletion, results in altered expression of nuclear genes involved in signalling, 
cellular architecture, metabolism, cell growth and differentiation, and apoptosis (Delsite et al., 
2002; Jahangir Tafrechi et al., 2005). Changes in the pattern of protein acetylation, due to 
changes in cell metabolism, signalling and other mechanisms, represent a more versatile and 
fast mechanism for cell adapted to various stimuli, than changes in protein expression.  
 
Figure 38. Acetylation is involved in multiple cellular functions (Xu and Zhao, 2011). 
From the analysis of the nineteen proteins identified, we were able to confirm the absence of 
changes in protein expression for three of them, eIF4AI, ENOI and GAPDH, between the 143B 
and 143B Rho0 cell lines. This datum implies that the changes observed in the 2-D gels, were 
due to changes in the degree of protein acetylating and not changes in the expression of the 
core protein.  
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eIF4AI protein is an ATP-dependent helicase that are required for efficient ribosome binding, 
and delivery of the mRNA template, process involved in the protein synthesis. Protein synthesis 
is a complex, tightly regulated process in eukaryotic cells and its deregulation is a hallmark of 
many cancers. Translational control occurs primarily at the rate-limiting initiation step, where 
ribosomal subunits are recruited to template mRNAs through the concerted action of several 
eukaryotic initiation factors (eIFs). Protein synthesis, appears to play an important role in 
tumour initiation and progression, since its overexpression can cooperate with oncogenes to 
accelerate cell transformation in cell lines and in animal models, and its levels are elevated in 
many human cancers (Lee and Pelletier, 2012; Nasr et al., 2013). However, the exact role of 
eIF4I acetylation in not well understood. Nevertheless, we observed a decrease of eIF4I 
acetylation in 143B Rho0 cell line, and this change in acetylation may represent an important 
role in the disruption of normal protein synthesis in consequence of mitochondrial dysfunction. 
ENOI is a key glycolytic enzyme in the cytoplasm of eukaryotic cells and is considered a 
multifunctional protein. ENOI catalyses the dehydration of 2-phosphoglycerate to 
phosphoenolpyruvate, in the last steps of the catabolic glycolytic pathway, and is also 
expressed on the surface of several cell types, where it acts as a plasminogen receptor, 
concentrating proteolytic plasmin activity on the cell surface (Pancholi, 2001). In addition, to 
this function as a glycolytic enzyme and plasminogen receptor, ENOI appears to have other 
cellular functions and subcellular localizations, distinct from its well-established function in 
glycolysis. Alterations in ENOI has been identified in diverse human pathologies, suggesting 
that it could be part of a group of universal sensors that response to multiple different stimuli 
(Díaz-Ramos et al., 2012). One of these stimuli may be the mitochondrial alterations that have 
been reported in a variety of human disorders. Thus, ENOI could be considered as a marker 
of pathological stress in a high number of diseases.  
Some of the more interesting and challenging issues regarding ENOI multifunction, that need 
to be addressed, are the role of ENOI as an inductor of intracellular signalling pathways, and 
the role of PTMs of ENOI and the implications on its subcellular distribution and function, and 
at this subject, the acetylation could provide an important clue to better understanding its 
multifunctional properties. 
In the past two decades, the glycolic enzyme GAPDH that was once considered 
“housekeeping” protein has been shown as being involved in many cellular processes in 
addition to the role it as in glycolysis, including: DNA repair, tRNA export, membrane fusion 
and transport, cytoskeletal dynamics and cell dead. Additionally, it has been reported that 
GAPDH is translocated to the nucleus, upon exposure to stressors, where participates in cell 
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death/dysfunction, and this translocation, to the nucleus, is mediated by acetylation at lysine 
160 of GAPDH (Tristan et al., 2011). In fact, we observed an increase in the acetylation level 
of GAPDH in 143B Rho0 cells. This cell line present a high oxidative stress due to the absence 
of mtDNA, and the increase in the acetylation levels of GAPDH could be a response to the cell 
to these high levels of stress.  
Furthermore, acetylation of the glycolytic/gluconeogenic enzyme GAPDH controls glucose flux 
in S.enterica, in which GAPDH acetylation favours glucose consumption through the induction 
of glycolysis, and GAPDH deacetylation, favours glucose production through gluconeogenesis. 
Despite a number of acetylated lysine residues in GAPDH were identified, their role in the 
control of glucose metabolism in mammalians is unknown. Understand if the acetylation of 
GAPDH also control glucose flux, may provide important clues to unveil some of the metabolic 
alterations reported in cancer in consequence of mitochondria dysfunction (Guan and Xiong, 
2011).  
Regarding the role of GAPDH as a “housekeeping” protein, and taking in account our data, 
GAPDH protein expression represented a good "housekeeping", once no differences were 
observed in the protein expression between the cell lines with different alterations in mtDNA 
although, the same is not true regarding  the levels of protein acetylation.  
Despite the large number acetylated proteins identified in mammalian cells, the number of 
KATs and KDACs is surprisingly small. The discrepancy between the number of acetylated 
proteins and the number of acetylation regulators suggests a highly interconnected acetylation 
regulation network and highlights the importance of the acetylation in cell physiology (Xu et al., 
2013).  
Mitochondrial dysfunction, due to mutations in mtDNA can lead to changes in the levels of 
some co-factors, namely NAD+ and acetyl-CoA of deacetylases, such as, Sirtuins, and thereby 
affecting protein acetylation. The acetylation is likely to be a coordinator of both cell signalling 
and cell metabolism, because of its versatile role in transcriptional and metabolic regulation 
(Figure 39). A better understanding of the role of acetylation, in metabolic coordination as well 
as the molecular understanding of the mechanisms by which it act, may provide new ways for 
the prevention and control of human tumours.  
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Figure 39. Link between acetylation, tumorigenesis and the Warburg effect. The interconnections between gene transcription, 
metabolism and metabolites are all coordinated by acetylation, deregulated coordination may alter both gene transcription and cell 
metabolism, two of the causal factors of the Warburg effect and tumorigenesis (Xu et al., 2013). 
5.8 Sirt 3 and SOD-2 protein expression, regulation of activation  
At this point, we found that mitochondrial dysfunction, caused either by mtDNA mutations or 
absence of mtDNA, as well as the presence of some mitochondrial variants (different mtDNA 
haplogroups) induces changes in cell metabolic profile, complex I activity, DNA methylation 
and protein acetylation. To test if mitochondrial variants and mitochondrial dysfunction 
influence the cellular stress response by modulating Sirt3 protein expression, we evaluated the 
expression of the Sirt3 in our cell lines. Sirt3 is a sensor of the energetic and redox, dependent 
on NAD+, this analysis make sense.  
We did not found differences in the cells with mtDNA belonging to different haplogroups, as 
well as in 143B Rho0 cell line, concerning Sirt3 protein expression. The difference found 
between the cell line displaying the mtDNA tRNA Leu (UUR) gene mutation (3243Cy 9.7) and the 
cell lines harbouring the mtDNA ND1 gene mutation (3571Cy 1 and 3571Cy 22), suggest that 
these mutations induces different cellular stress in the mitochondria.  In fact, the 3243Cy 9.7 
cell line presented a higher level of ROS production (data not shown) and it is known that the 
increase of ROS levels stimulates Sirt3 transcription (Chen et al., 2011).  
Considering the results observed in 143B Rho0 cells, which are intrinsically exposed to very 
stressful conditions due to the absence of mtDNA, and consequently to mitochondrial 
dysfunctions, it may seem inconsistent that these cells keeps the Sirt3 protein levels. One 
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possible explanation, already proposed by D’Aquila et al, is that Rho0 cells adopt a series of 
mechanisms to compensate their intrinsic oxidative stress status. 
Mitochondrial manganese superoxide dismutase (SOD-2) is an important antioxidant enzyme, 
and SOD-2 deficiency is associated with several human diseases (Miao and Clair, 2009). SOD-
2 is acetylated at Lys 68 and this acetylation decreases its activity. Sirt3 binds to SOD-2, 
deacetylating and activating it (Figure 40). 143B Rho0 cell line was the only cell line, in study, 
that presented a significant increase in the SOD-2 protein expression level. This observation 
may be related with the oxidative stress induced SOD-2 expression, and is believed to be an 
important cellular defence mechanism against oxidative stress.  
The increase in SOD-2 protein expression levels and activity observed in 143B Rho0 cell line, 
enforces the hypothesis that these cells have an intrinsic mechanism to deal with oxidative 
stress. In fact, several studies have been reporting the resistance of mtDNA-depleted cells to 
apoptosis induced by oxidative stress (Ferraresi et al., 2008; Park et al., 2004; Quinzii et al., 
2010).  
The cell lines displaying mutations in mtDNA presented a lower activity of SOD-2, these data 
may be explained by the absence of an intrinsic mechanism to handle with oxidative stress in 
these cells. Mitochondria dysfunction, due to mtDNA mutations may cause damage in SOD-2 
protein and thus inhibiting their activity. What we observe in 143B Rho0 cells may be a well-
balanced mechanism between the overproduction of ROS and the SOD2 activity. 
 
 
Figure 40. A model on SIRT3-mediated SOD2 activation (Adapted from Qiu et al., 2010). 
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6.1 Conclusion  
In summary, there is a strong motivation to explore the epigenetic changes that occur as 
consequence of alterations in mtDNA, given the extensive number of mitochondrial diseases. 
These epigenetic changes may serve to explain the observed phenotypic heterogeneity, 
variable penetrance and environmental triggers in this group of disorders. Indeed, the 
interrelationship between mtDNA and cell metabolism have an essential role in the 
maintenance of the levels of essential co-factors for epigenetic mechanisms, such as DNA 
methylation and protein acetylation.  
In this work, we showed that mtDNA variants and mitochondrial dysfunction, caused either by 
mtDNA mutations or absence of mtDNA, leads to changes in OXPHOS efficiency, in ATP 
production and in the levels of several metabolites from several metabolic pathways. 
Furthermore, we showed that changes in the levels of metabolites, namely changes in the level 
of those that serve as co-factor of several enzymes involved in epigenetic regulation and PTMs, 
disturb the epigenetic landscape of the cell. Thus, the data presented suggest that 
mitochondrial dysfunction lead cells to reset their cellular programme in order to maintain cell 
homeostasis and viability.  
We have demonstrated that nDNA methylation pattern can be modified as a consequence of 
mtDNA variants and mitochondria dysfunction caused either by mutations in mtDNA or 
absence of mtDNA. These data suggest the presence of direct communication routes, between 
the mitochondrial and the nuclear genomes, since we observed changes in the expression of 
nuclear encoded genes in cell lines with mtDNA mutations.  
Mitochondrial dysfunction caused by depletion of mtDNA leads the cells to readjust several 
cellular processes in order to survive and maintain cell homeostasis. Actually, these cells 
presented changes concerning acetylation of proteins involved in several cellular processes, 
such as metabolism, protein synthesis, cellular architecture and DNA repair. The acetylation of 
proteins can act as a coordinator of both cell signalling and metabolism, because of it versatile 
role in transcriptional and metabolic regulation.  
Actually, we found differences concerning DNA methylation and proteins PTMs, as well as 
changes in the expression of nuclear genes in cell lines with mtDNA mutations/variants and 
DNA depletion, suggesting that mitochondrial dysfunction may have a huge impact in cell 
physiology.  
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Thus, it matters now realize to what extent these changes in the programme of the cell can be 
used to deal with diseases in which mitochondrial dysfunction is common, namely cancer 
diabetes and degenerative diseases.  
6.2 Future perspectives  
While performing the work presented in this thesis, several questions were raised concerning 
validations, and complementary work should be performed in order to clarify some issues. In 
order to confirm the changes in complex I activity, especially in the cell lines harbouring the 
mutations in mtDNA and the cell line devoid of mtDNA, more suitable analysis should be 
performed, namely to perform, in particular, to study the complex I activity using mitochondrial 
extracts, and even to study the activity of all the OXPHOS complexes. The use mitochondrial 
extracts, allow to overcoming some putative differences in the loading of mitochondrial proteins 
between the cell line samples, and the same is true for ATP production levels analysis.  
Actually, concerning ATP production and in order to establish an accurate relationship between 
complex I activity and ATP production, we should measure, not only the global ATP levels, but, 
also the production of mitochondrial ATP, as well the complex V activity. 
Although we observed differences concerning the DNA methylation status in different cell lines, 
a whole genome methylation analysis would be a better hypothesis to confirm the differences 
observed, since we have access to the list of genes differentially methylated between cell lines. 
This information can be crucial to better understand the link between mutation/variants in 
mtDNA and changes in the DNA methylation pattern.  
It would be interesting to analyse if the different cell lines harbouring mtDNA variants and 
mitochondrial dysfunction, caused either by mtDNA mutations or absence of mtDNA, would 
have some alteration in the activity of the enzymes involved in the one carbon metabolism. 
These results may provide new clues for the differences observed in the methylation status of 
different cell lines.  
Histone lysine methylation is an integral part of the PTMs of histone tails, and is important for 
chromatin organization and gene transcription regulation. In order to clarify the reason behind 
the differences between the expression of the genes related with the one carbon metabolism, 
the study of the repressive marks of histone should be performed. Additionally, because histone 
repressive marks can promote DNA methylation and vice versa, it should be interesting to study 
the temporal relationship of histone and DNA methylation. 
The lack of biological replicates in the 5-hmC analysis should also be filled. It will be very 
important confirm if the cell lines that showed the highest methylation levels are the same that 
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present a reduction of the 5-hmC levels. Moreover, the activity and protein expression levels 
of the enzymes involved in the hydroxylation of 5-mC to 5-hmC, the TET enzymes, should be 
accessed. This information could be important to understand the relationship between the 
balance of methylation and demethylation pathways as well the final outcome. 
Concerning the rate of protein acetylation, it will be important to confirm the differences found 
between the cell lines, namely for those in which absence of differences in the protein 
expression levels were confirmed: ENOI and eIF4AI.  
Furthermore, in the analysis of the acetylated proteins, we did not found differences in the 
acetylation of histones. A more sensitive and directed study should be performed in order to 
access the putative role of mitochondrial dysfunction in this process.  
In addition, to provide more evidences to support the hypothesis, that acetylation is likely a 
coordinator of both cell signalling and metabolism, the same analysis that was performed, in 
the 143B and 143B Rho0 cell lines, concerning protein acetylation, should be carried out for the 
other cell lines. 
In order to confirm the presence, in the 143B Rho0 cell line, of an intrinsic mechanism to deal 
with their intrinsic stress status, the activity of Sirt3 should also be carried out. 
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